U.S. patent application number 13/488212 was filed with the patent office on 2013-07-18 for oligonucleotide amplification primers for targeting oncogenic hpv.
This patent application is currently assigned to GENERA BIOSYSTEMS LIMITED. The applicant listed for this patent is ZAHEER KHAN, DANIEL J. PARK, KARL F. POETTER. Invention is credited to ZAHEER KHAN, DANIEL J. PARK, KARL F. POETTER.
Application Number | 20130184170 13/488212 |
Document ID | / |
Family ID | 39831523 |
Filed Date | 2013-07-18 |
United States Patent
Application |
20130184170 |
Kind Code |
A1 |
PARK; DANIEL J. ; et
al. |
July 18, 2013 |
OLIGONUCLEOTIDE AMPLIFICATION PRIMERS FOR TARGETING ONCOGENIC
HPV
Abstract
The present invention relates generally to the field of
diagnostic and detection assays. More particularly, the present
invention provides methods and reagents including biochips for
detecting the presence of, or distinguishing between, one or more
analytes in a sample.
Inventors: |
PARK; DANIEL J.; (CLIFTON
HILL VIC, AU) ; KHAN; ZAHEER; (MANUKAU, NZ) ;
POETTER; KARL F.; (NORTHCOTE VIC, AU) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
PARK; DANIEL J.
KHAN; ZAHEER
POETTER; KARL F. |
CLIFTON HILL VIC
MANUKAU
NORTHCOTE VIC |
|
AU
NZ
AU |
|
|
Assignee: |
GENERA BIOSYSTEMS LIMITED
SCORESBY VIC
AU
|
Family ID: |
39831523 |
Appl. No.: |
13/488212 |
Filed: |
June 4, 2012 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12594817 |
Apr 30, 2010 |
8278429 |
|
|
PCT/US2008/004441 |
Apr 4, 2008 |
|
|
|
13488212 |
|
|
|
|
60910381 |
Apr 5, 2007 |
|
|
|
60910373 |
Apr 5, 2007 |
|
|
|
Current U.S.
Class: |
506/9 ; 435/5;
506/16; 506/30 |
Current CPC
Class: |
C12Q 1/708 20130101;
C12Q 1/701 20130101 |
Class at
Publication: |
506/9 ; 506/16;
506/30; 435/5 |
International
Class: |
C12Q 1/70 20060101
C12Q001/70 |
Claims
1. A headset for detecting a strain of HPV and/or for
differentiating between two or more strains of HPV, wherein the
headset comprises a plurality of families or a plurality of subsets
of beads having: (a) at least two subsets of beads, wherein each
subset of beads is physiochemically distinguishable from any other
bead subset based on at least size; or (b) at least one subset of
beads having at least two families, wherein the beads in a bead
subset are homogeneous in size with respect to each other, and are
physiochemically distinguishable into two or more families of beads
based on the level of labelling each contains, or (c) a combination
of said families of beads and said subsets of beads; and wherein:
the beads within each bead family of a subset are each coupled to
an optionally-labelled nucleic acid capture probe capable of
binding to a HPV strain-specific region of an HPV genome or,
optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and each family of
beads is specific for the detection of a strain of HPV different
from any other bead family in the beadset; wherein said beadset is
capable of identifying one or more specific strains of HPV through
analysis of bead size, fluorescent intensity, or sequence
discrimination of the at least one bead family or bead subset,
using flow cytometry.
2. The beadset of claim 1, wherein the bead sizes are selected from
the group consisting of: 3.0 .mu.m, 3.5 .mu.m, 4.1 .mu.m, 5.0
.mu.m, 5.6 .mu.m and 6.8 .mu.m.
3. The beadset of claim 1, wherein the bead sizes are selected from
the group consisting of: 3.0 .mu.m, 3.5 .mu.m, 3.77 .mu.m, 5.0
.mu.m, 5.6 .mu.m and 6.8 .mu.m.
4. The beadset of claim 1 wherein the labelled beads are labelled
with a fluorochrome selected from the group consisting of:
hydroxycoumarin, aminocoumarin, methoxycoumarin, cascade blue,
Lucifer yellow, NBD, Phycoerythrin (PE), PerCP, allophycocyanin,
Hoechst 33342, DAP1, SYTOX Blue, Hoechst 33258, chromomycin A3,
mithramycin, YOYO-I, SYTOX green, SYTOX orange, 7-AAD, acridine
orange, TOTO-1, To-PRO-1, thiazole orange, TOTO-3, TO-PRO-3, LDS
751, Alexa Fluoro-350, Alexa Fluoro-430, Alexa Fluoro-488, Alexa
Fluoro-532, Alexa Fluoro-546, Alexa Fluoro-555, Alexa Fluoro-556,
Alexa Fluoro-594, Alexa Fluoro-633, Alexa Fluoro-647, Alexa
Fluoro-660, Alexa Fluoro-680, Alexa Fluoro-700 and Alexa
Fluoro-750, BoDipy 630/650 and BoDipy 650/665, the CY dyes Cy2,
Cy3, Cy3.5, Cy5, Cy 5.5 and Cy7, 6-FAM (Fluorescein), PE-Cy5,
PE-Cy7, Fluorescein dT, Hexachlorofluorescein (Hex),
6-carboxy-4',5'-dichloro-2', 7-dimethoxyfluorescein (JOE), Oregon
green dyes 488-X and 514, Rhodamine dyes X-Rhodamine, Lissamine
Rhodamine B, Rhodamine Green, Rhodamine Red, and ROX, TRITC,
Tetramethylrhodamine (TMR), Carboxytetramethylrhodamine (TAMRA),
Tetrachlorofluorescein (TET), Red 6B, Fluor X, BODIPY-FL, SYBR
Green I dye, and Texas Red.
5. The beadset of claim 4 wherein the labelled beads are labelled
with TMR.
6. The beadset of claim 1 comprising to 2 to 17 families of
beads.
7. The beadset of claim 1, wherein the beadset comprises 17
families of beads.
8. The beadset of claim 1 wherein the two or more HPV strains are
selected from the group consisting of strains 6, 11, 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
9. The beadset of claim 1, wherein the nucleic acid capture probe
is selected from the list of sequences of Table 2.
10. A method for preparing a headset for use in detecting a strain
of HPV and/or differentiating between two or more strains of HPV,
the method comprising selecting a plurality of families or subsets
of beads based on size, fluorescent intensity, or both, comprising
providing: (a) at least two subsets of beads, wherein each subset
of beads is physiochemically distinguishable from any other bead
subset based on at least size; or (b) at least one subset of beads
having at least two families, wherein the beads in a bead subset
are homogeneous in size with respect to each other, and are
physiochemically distinguishable into two or more families of beads
based on the level of labelling each contains, or (c) a combination
of said families of beads and said subsets of beads; and wherein:
the beads within each bead family of a subset are each coupled to
an optionally-labelled nucleic acid capture probe capable of
binding to a HPV strain-specific region of an HPV genome or,
optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and each family of
beads is specific for the detection of a strain of HPV different
from any other bead family in the beadset; and mixing the at least
two families or at least two subsets of beads together to produce a
beadset that permits identification of a specific strain of HPV
through analysis of bead size, fluorescent intensity, or sequence
discrimination of the at least one bead family or bead subset,
using flow cytometry.
11. A method for diagnosing HPV infection in a human subject, said
method comprising: (i) obtaining a biological sample from the human
subject which putatively comprises HPV; (ii) isolating nucleic acid
from said sample; (iii) amplifying the nucleic acid from said
sample using primers which generate an amplicon which is distinct
for said analyte or a particular strain of said analyte; (iv)
optionally amplifying a control nucleic acid sequence from the
genomic DNA of the human subject; (v) optionally effecting
labelling of the amplicon(s) recited at steps (iii) and/or (iv);
(vi) hybridizing the labelled amplicon(s) to a beadset of reactants
wherein each member of the beadset comprises a nucleic acid
molecule having complementarity to a nucleotide sequence of HPV or
a particular strain of HPV or a control nucleotide sequence, bound
or otherwise associated with a physiochemically distinguishable
substrate; and (vii) determining to which of the reactants an
amplicon has bound; wherein the association of an amplicon with a
particular reactant is indicative of HPV infection in the human
subject.
12. A method for determining the risk of a human subject developing
a disease associated with one or more strains of HPV said method
comprising: (i) obtaining a biological sample from the human
subject which putatively comprises HPV; (ii) isolating nucleic acid
from said sample; (iii) amplifying the nucleic acid from said
sample using primers which generate an amplicon which is distinct
for said analyte or a particular strain of said analyte; (iv)
optionally amplifying a control nucleic acid sequence from the
genomic DNA of the human subject; (v) optionally effecting
labelling of the amplicon(s) recited at steps (iii) and/or (iv);
(vi) hybridizing the labelled amplicon(s) to a beadset of reactants
wherein each member of the beadset comprises a nucleic acid
molecule having complementarity to a nucleotide sequence of HPV or
a particular strain of HPV or a control nucleotide sequence, bound
or otherwise associated with a physiochemically distinguishable
substrate; and (vii) determining to which of the reactants an
amplicon has bound; wherein the association of an amplicon with a
particular reactant comprising a polynucleotide which is
complementary to a strain of HPV associated with a particular
disease, is indicative of an increased risk said disease in the
subject.
13. A method for diagnosing HPV infection in a human subject, said
method comprising: (i) obtaining a biological sample from the human
subject which putatively comprises HPV; (ii) isolating nucleic acid
from said sample; (iii) amplifying the nucleic acid from said
sample using primers which generate an amplicon which is distinct
for said analyte or a particular strain of said analyte; (iv)
optionally amplifying a control nucleic acid sequence from the
genomic DNA of the human subject; (v) hybridizing the labelled
amplicon(s) to a beadset of reactants wherein each member of the
beadset comprises a nucleic acid molecule having complementarity to
a nucleotide sequence of HPV or a particular strain of HPV or a
control nucleotide sequence, bound or otherwise associated with a
physiochemically distinguishable substrate and wherein the
hybridizing occurs in the presence of at least one signal
oligonucleotide sequence; and (vi) determining to which of the
reactants an amplicon has bound; wherein the association of an
amplicon with a particular reactant is indicative of HPV infection
in the human subject.
14. A method of claim 13, wherein the beadset of reactants
comprises a plurality of families or a plurality of subsets of
beads having: (a) at least two subsets of beads, wherein each
subset of beads is physiochemically distinguishable from any other
bead subset based on at least size; or (b) at least one subset of
beads having at least two families, wherein the beads in a bead
subset are homogeneous in size with respect to each other, and are
physiochemically distinguishable into two or more families of beads
based on the level of labelling each contains, or (c) a combination
of said families of beads and said subsets of beads; and wherein:
the beads within each bead family of a subset are each coupled to
an optionally-labelled nucleic acid capture probe capable of
binding to a HPV strain-specific region of an HPV genome or,
optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and each family of
beads is specific for the detection of a strain of HPV different
from any other bead family in the beadset; wherein said beadset is
capable of identifying one or more specific strains of HPV through
analysis of bead size, fluorescent intensity, or sequence
discrimination of the at least one bead family or bead subset,
using flow cytometry.
15. A method for determining the risk of a human subject developing
a disease associated with one or more strains of HPV said method
comprising: (i) obtaining a biological sample from the human
subject which putatively comprises HPV; (ii) isolating nucleic acid
from said sample; (iii) amplifying the nucleic acid from said
sample using primers which generate an amplicon which is distinct
for said analyte or a particular strain of said analyte; (iv)
optionally amplifying a control nucleic acid sequence from the
genomic DNA of the human subject; (v) hybridizing the labelled
amplicon(s) to a beadset of reactants wherein each member of the
beadset comprises a nucleic acid molecule having complementarity to
a nucleotide sequence of HPV or a particular strain of HPV or a
control nucleotide sequence, bound or otherwise associated with a
physiochemically distinguishable substrate and wherein the
hybridizing occurs in the presence of at least one signal
oligonucleotide sequence; and (vi) determining to which of the
reactant an amplicon has bound; wherein the association of an
amplicon with a particular reactant comprising a polynucleotide
which is complementary to a strain of HPV associated with a
particular disease, is indicative of an increased risk said disease
in the subject.
16. A method of claim 15, wherein the beadset of reactants
comprises a plurality of families or a plurality of subsets of
beads having: (a) at least two subsets of beads, wherein each
subset of beads is physiochemically distinguishable from any other
bead subset based on at least size; or (b) at least one subset of
beads having at least two families, wherein the beads in a bead
subset are homogeneous in size with respect to each other, and are
physiochemically distinguishable into two or more families of beads
based on the level of labelling each contains, or (c) a combination
of said families of beads and said subsets of beads; and wherein:
the beads within each bead family of a subset are each coupled to
an optionally-labelled nucleic acid capture probe capable of
binding to a HPV strain-specific region of an HPV genome or,
optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and each family of
beads is specific for the detection of a strain of HPV different
from any other bead family in the beadset; wherein said beadset is
capable of identifying one or more specific strains of HPV through
analysis of bead size, fluorescent intensity, or sequence
discrimination of the at least one bead family or bead subset,
using flow cytometry.
17. A method for diagnosing HPV infection in a human subject, said
method comprising: (i) obtaining a biological sample from the human
subject which putatively comprises HPV; (ii) isolating nucleic acid
from said sample; (iii) amplifying the nucleic acid from said
sample using primers which generate an amplicon which is distinct
for said analyte or a particular strain of said analyte; (iv)
optionally amplifying a control nucleic acid sequence from the
genomic DNA of the human subject; (v) optionally effecting
labelling of the amplicon(s) recited at steps (iii) and/or (iv);
(vi) hybridizing the labelled amplicon(s) to a beadset of reactants
wherein each member of the beadset comprises a nucleic acid
molecule having complementarity to a nucleotide sequence of HPV or
a particular strain of HPV or a control nucleotide sequence, bound
or otherwise associated with a physiochemically distinguishable
substrate and wherein the hybridizing occurs in the presence of at
least one blocking oligonucleotide sequence; and (vii) determining
to which of the reactants an amplicon has bound; wherein the
association of an amplicon with a particular reactant is indicative
of HPV infection in the human subject.
18. A method of claim 17, wherein the beadset of reactants
comprises a plurality of families or a plurality of subsets of
beads having: (a) at least two subsets of beads, wherein each
subset of beads is physiochemically distinguishable from any other
bead subset based on at least size; or (b) at least one subset of
beads having at least two families, wherein the beads in a bead
subset are homogeneous in size with respect to each other, and are
physiochemically distinguishable into two or more families of beads
based on the level of labelling each contains, or (c) a combination
of said families of beads and said subsets of beads; and wherein:
the beads within each bead family of a subset are each coupled to
an optionally-labelled nucleic acid capture probe capable of
binding to a HPV strain-specific region of an HPV genome or,
optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and each family of
beads is specific for the detection of a strain of HPV different
from any other bead family in the beadset; wherein said beadset is
capable of identifying one or more specific strains of HPV through
analysis of bead size, fluorescent intensity, or sequence
discrimination of the at least one bead family or bead subset,
using flow cytometry.
19. A method for determining the risk of a human subject developing
a disease associated with one or more strains of HPV said method
comprising: (i) obtaining a biological sample from the human
subject which putatively comprises HPV; (ii) isolating nucleic acid
from said sample; (iii) amplifying the nucleic acid from said
sample using primers which generate an amplicon which is distinct
for said analyte or a particular strain of said analyte; (iv)
optionally amplifying a control nucleic acid sequence from the
genomic DNA of the human subject; (v) optionally effecting
labelling of the amplicon(s) recited at steps (iii) and/or (iv);
(vi) hybridizing the labelled amplicon(s) to a beadset of reactants
wherein each member of the beadset comprises a nucleic acid
molecule having complementarity to a nucleotide sequence of HPV or
a particular strain of HPV or a control nucleotide sequence, bound
or otherwise associated with a physiochemically distinguishable
substrate and wherein the hybridizing occurs in the presence of at
least one blocking oligonucleotide sequence; and (vii) determining
to which of the reactant an amplicon has bound; wherein the
association of an amplicon with a particular reactant comprising a
polynucleotide which is complementary to a strain of HPV associated
with a particular disease, is indicative of an increased risk said
disease in the subject.
20. A method of claim 19, wherein the beadset of reactants
comprises a plurality of families or a plurality of subsets of
beads having: (a) at least two subsets of beads, wherein each
subset of beads is physiochemically distinguishable from any other
bead subset based on at least size; or (b) at least one subset of
beads having at least two families, wherein the beads in a bead
subset are homogeneous in size with respect to each other, and are
physiochemically distinguishable into two or more families of beads
based on the level of labelling each contains, or (c) a combination
of said families of beads and said subsets of beads; and wherein:
the beads within each bead family of a subset are each coupled to
an optionally-labelled nucleic acid capture probe capable of
binding to a HPV strain-specific region of an HPV genome or,
optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and each family of
beads is specific for the detection of a strain of HPV different
from any other bead family in the beadset; wherein said beadset is
capable of identifying one or more specific strains of HPV through
analysis of bead size, fluorescent intensity, or sequence
discrimination of the at least one bead family or bead subset,
using flow cytometry.
21. A method for diagnosing HPV infection in a human subject, said
method comprising: (i) obtaining a biological sample from the human
subject which putatively comprises HPV; (ii) isolating nucleic acid
from said sample; (iii) amplifying the nucleic acid from said
sample using primers which generate an amplicon which is distinct
for said analyte or a particular strain of said analyte; (iv)
optionally amplifying a control nucleic acid sequence from the
genomic DNA of the human subject; (v) hybridizing the labelled
amplicon(s) to a beadset of reactants wherein each member of the
beadset comprises a nucleic acid molecule having complementarity to
a nucleotide sequence of HPV or a particular strain of HPV or a
control nucleotide sequence, bound or otherwise associated with a
physiochemically distinguishable substrate and wherein the
hybridizing occurs in the presence of at least one signal
oligonucleotide sequence and at least one blocking oligonucleotide
sequence; and (vi) determining to which of the reactants an
amplicon has bound; wherein the association of an amplicon with a
particular reactant is indicative of HPV infection in the human
subject.
22. A method of claim 13, wherein the beadset of reactants a
plurality of families or a plurality of subsets of beads having:
(a) at least two subsets of beads, wherein each subset of beads is
physiochemically distinguishable from any other bead subset based
on at least size; or (b) at least one subset of beads having at
least two families, wherein the beads in a bead subset are
homogeneous in size with respect to each other, and are
physiochemically distinguishable into two or more families of beads
based on the level of labelling each contains, or (c) a combination
of said families of beads and said subsets of beads; and wherein:
the beads within each bead family of a subset are each coupled to
an optionally-labelled nucleic acid capture probe capable of
binding to a HPV strain-specific region of an HPV genome or,
optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and each family of
beads is specific for the detection of a strain of HPV different
from any other bead family in the beadset; wherein said beadset is
capable of identifying one or more specific strains of HPV through
analysis of bead size, fluorescent intensity, or sequence
discrimination of the at least one bead family or bead subset,
using flow cytometry.
23. A method for determining the risk of a human subject developing
a disease associated with one or more strains of HPV said method
comprising: (i) obtaining a biological sample from the human
subject which putatively comprises HPV; (ii) isolating nucleic acid
from said sample; (iii) amplifying the nucleic acid from said
sample using primers which generate an amplicon which is distinct
for said analyte or a particular strain of said analyte; (iv)
optionally amplifying a control nucleic acid sequence from the
genomic DNA of the human subject; (v) hybridizing the labelled
amplicon(s) to a beadset of reactants wherein each member of the
beadset comprises a nucleic acid molecule having complementarity to
a nucleotide sequence of HPV or a particular strain of HPV or a
control nucleotide sequence, bound or otherwise associated with a
physiochemically distinguishable substrate and wherein the
hybridizing occurs in the presence of at least one signal
oligonucleotide sequence and at least one blocking oligonucleotide
sequence; and (vi) determining to which of the reactant an amplicon
has bound; wherein the association of an amplicon with a particular
reactant comprising a polynucleotide which is complementary to a
strain of HPV associated with a particular disease, is indicative
of an increased risk said disease in the subject.
24. A method of claim 13, wherein the beadset of reactants a
plurality of families or a plurality of subsets of beads having:
(a) at least two subsets of beads, wherein each subset of beads is
physiochemically distinguishable from any other bead subset based
on at least size; or (b) at least one subset of beads having at
least two families, wherein the beads in a bead subset are
homogeneous in size with respect to each other, and are
physiochemically distinguishable into two or more families of beads
based on the level of labelling each contains, or (c) a combination
of said families of beads and said subsets of beads; and wherein:
the beads within each bead family of a subset are each coupled to
an optionally-labelled nucleic acid capture probe capable of
binding to a HPV strain-specific region of an HPV genome or,
optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and each family of
beads is specific for the detection of a strain of HPV different
from any other bead family in the beadset; wherein said beadset is
capable of identifying one or more specific strains of HPV through
analysis of bead size, fluorescent intensity, or sequence
discrimination of the at least one bead family or bead subset,
using flow cytometry.
25. An oligonucleotide amplification primer pair for targeting
oncogenic HPV, wherein the forward primer of the primer pair is
selected from the group consisting of: TABLE-US-00011 TR TTT GTT
ACT GTK GTD GAT ACY A; CAR YTR TTT GTT ACT GTK GTD GAT A; CAR YTR
TTT GTT ACT GTK GTD GA; AAY CAR YTR TTT GTT ACT GTK GT; TTT GTT ACT
GTK GTD GAT ACY AC HCG; TTT GTT ACT GTK GTD GAT ACY AC HCG YAG; GTK
GTD GAT ACY AC HCG YAG TAC and GTD GAT ACY AC HCG YAG TAC HAA;
and the reverse primer of the primer pair is selected from the
group consisting of: TABLE-US-00012 TGA AAA ATA AAY TGY AAA TCA TAT
TCY TCM MCA TG; CAY ARY TGA AAA ATA AAY TGY AAA TC; TR CAY ARY TGA
AAA ATA AAY TG; and TR CAY ARY TGA AAA ATA AA;
wherein the forward and reverse primers are each optionally
conjugated to a heel at the 5' terminus of the primer.
26. A primer pair according to claim 25, wherein at least one of
the forward and reverse primers is conjugated to a heel at the 5'
terminus of the primer.
27. A primer pair of claim 25, wherein the forward primer heel is
selected from the group consisting of: CAATCAGC, ACAAT, GGAACAAT,
GGAAC, CAGCTT, ATTACC, CTGTT, /5 Phos/CAATCAGC, /5 Phos/ACAAT, /5
Phos/GGAACAAT, /5 Phos/GGAAC, /5Phos/CAGCTT, 5Phos/ATTACC, and
/5Phos/CTGTT.
28. A primer pair of claim 25, wherein the reverse primer heel is
selected from the group consisting of: ACTCACTATAGG,
AATACGACTCACTATAGG, TCTAATACGACTCACTATAGG,
AATTCTAATACGACTCACTATAGG, /5 AmMC6/ACTCACTATAGG, /5
AmMC6/AATACGACTCACTATAGG, /5 AmMC6/TCTAATACGACTCACTATAGG, and /5
AmMC6/AATTCTAATACGACTCACTATAGG.
29. An oligonucleotide amplification primer pair of claim 25,
containing an optional heel nucleic acid sequence, wherein the
forward primer of the primer pair is selected from the group
consisting of: CAR YTR TTT GTT ACT GTK GTD GA, optionally having a
ACAAT, /5Phos/ACAAT, GGAACAAT, or a /5Phos/GGAACAAT conjugated to
the 5' terminus of the primer; and GTD GAT ACY AC HCG YAG TAC HAA,
optionally having a CTGTT or /5 Phos/CTGTT conjugated to the 5'
terminus of the primer.
30. An oligonucleotide amplification primer pair of claim 25,
containing an optional heel nucleic acid sequence, wherein the
reverse primer of the primer pair is selected from the group
consisting of: TGA AAA ATA AAY TGY AAA TCA TAT TCY TCM MCA TG,
optionally having a ACTCACTATAGG or /5AmMC6/ACTCACTATAGG conjugated
to the 5' terminus of the primer, TR CAY ARY TGA AAA ATA AAY TG,
optionally having a TCTAATACGACTCACTATAGG or
/5AmMC6/TCTAATACGACTCACTATAGG conjugated to the 5' terminus of the
primer; and TR CAY ARY TGA AAA ATA AAY TG, optionally having a
TCTAATACGACTCACTATAGG or /5AmMC6/TCTAATACGACTCACTATAGG conjugated
to the 5' terminus of the primer.
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a divisional of U.S. application Ser.
No. 12/594,817, filed Oct. 5, 2009 which is incorporated herein by
reference and which is the U.S. National Phase of International
Application No.: PCT/US 2008/004441, filed Apr. 4, 2008,
designating the U.S. and published in English on Oct. 16, 2008 as
WO 2008/124091, which claims the benefit of U.S. Provisional
Application No. 60/910,381, filed Apr. 5, 2007 and U.S. Provisional
Application No. 60/910,373, filed Apr. 5, 2007.
FIELD OF THE INVENTION
[0002] The present invention relates generally to the field of
diagnostic and detection assays. More particularly, the present
invention provides methods, and reagents including biochips for
detecting the presence of, or distinguishing between, one or more
analytes in a sample.
BACKGROUND OF THE INVENTION
[0003] Bibliographical details of references provided in the
subject specification are listed at the end of the
specification.
[0004] Reference to any prior art in this specification is not, and
should not be taken as, an acknowledgement or any form of
suggestion that this prior art forms part of the common general
knowledge in any country.
[0005] The need for rapid and reliable screening methods for
detecting multiple analytes in a single assay is vital not only in
the fields of clinical diagnosis, but also for use in screening,
for example, for environmental toxins and drug screening.
[0006] One such area which is desperately in need of improved
screening methods and reagents is in the field of infectious
diseases. For example, a conservative estimate of the world use of
diagnostic tests for sexually transmitted diseases, such as Human
Papilloma Virus (HPV), is approximately 20,000,000 tests per
year.
[0007] Many of the existing tests for screening for the causes of
infectious diseases are time consuming, labor intensive, expensive,
often specific for only one specific pathogen and/or cannot
differentiate between different strains of pathogens.
[0008] HPV is the main causative pathogen for cervical cancer.
However, the HPV taxon comprises many "strains" of the pathogen,
only some of which are associated with the development of cervical
cancer and other carcinomas. Accordingly, the strains of HPV are
typically classified as either "high risk" strains, including the
13 strains which account for roughly 98% of cervical cases, or "low
risk" strains which are not typically associated with the
development of cervical cancer.
[0009] Currently, cervical cancer is detected by a Pap smear. In
this technique, cells are collected from the cervix by scraping or
washing. These cells are then placed on a glass microscope slide to
produce the "smear". A pathologist then examines the slide, looking
for aberrant cells. The Pap smear, however, is a somewhat
unsatisfactory assay for unequivocally determining cervical cancer
risk, as the technique has a false negative rate of approximately
20% and the technique cannot distinguish "high risk" and "low risk"
taxon.
[0010] Many of the reagents and/or methods for detection of HPV
suffer from high associated costs and/or consume significant
amounts of time to complete. More rapid and/or simplified analyses
having lower overall costs and easier application are needed. The
present invention is directed to these and other important
ends.
SUMMARY OF THE INVENTION
[0011] The present invention provides assays which enable the
detection of one or more analytes and/or which differentiate
between members within a class of analytes. In particular,
multiplexing analysis based on the properties of the analytes and
of the assay components is employed to identify or distinguish
between analytes.
[0012] Accordingly, certain aspects of the present invention
provides beadsets for detecting one or more analytes and/or for
differentiating between two or more members within a class of
analytes, wherein the beadset comprises a plurality of families or
subsets of beads wherein: [0013] (a) the beads of each subset are
homogeneous with respect to size; [0014] (b) the beads within each
subset are coupled to a reactant that will specifically react with
a given analyte of interest in a sample to be tested; [0015] (c)
the reactant on each bead is labelled with the same label with each
subset of beads having a different fluorescent intensity to create
a heterogeneous mixture of subsets of beads based on fluorescent
intensity; and [0016] (d) at least two subsets of beads are mixed
together to produce a beadset, wherein the subset identity and
therefore the reactant to which the bead has been coupled is
identifiable by flow cytometry based on size, fluorescent intensity
and analyte discrimination.
[0017] In other aspects, the present invention contemplates methods
for detecting and/or differentiating between two or more analytes
in a sample, comprising the steps of:
[0018] (a) contacting the sample with a beadset specific for the
analytes of interest;
[0019] (b) incubating said beadset with said sample for a time and
under conditions sufficient to allow said analyte(s) in said sample
to react specifically with a reactant on a bead within said
beadset; and
[0020] (c) detecting and/or differentiating analytes in the sample
which are bound to a reactant on said bead.
[0021] In some other aspects, the reactants may be labelled with
one or more fluorochromes that further allow differentiation
between members within a class of analytes. In certain preferred
aspects, the present invention provides methods and beadsets which
are able to detect and/or distinguish between analytes within a
biological sample, wherein the analytes are specific for an
infectious pathogen.
[0022] Biological samples contemplated herein include blood, serum,
saliva, faeces, urine, tissue fluid, semen, exudate, pus, and
respiratory fluid and mucus and swabs from topical sores, cancers
and lesions.
[0023] The term "pathogen" refers to a microorganism or virus which
infects or colonizes a sample. Exemplary pathogens include viruses,
bacteria, fungi and eukaryotic microorganisms. A virus includes a
Lentivirus (e.g. AIDS virus, HIV-I, HIV-II, HTLV-IV), Retrovirus
and avian flu virus. In some preferred embodiments, "pathogen"
includes a microorganism or virus which infects a multicellular
organism such as an animal or plant. Accordingly, in some
embodiments, the analyte may be regarded as an animal or plant
pathogen. However, the present invention encompasses the detection
and/or differentiation of non-pathogenic entities which colonize
multicellular organisms such as symbionts, endophytes,
gastrointestinal colonists, and the like. The methods of the
present invention are also applicable to the detection of analytes
in a sample which are indicative of the presence of therapeutic
agents or substances of abuse. The methods and reagents of the
present invention may also be used in the detection of an analyte
in a sample which is not derived from a biological sample isolated
from an animal or a plant. As such, the reagents and methods of the
present invention also extend to the detection of one or more
analytes and/or differentiation between analytes in environmental
samples, including air, water and soil samples, including
extraterrestrial soil, dust or like samples, industrial samples and
the like, in addition to the biological samples listed above.
[0024] In certain embodiments, the present invention provides for
diagnostic methods and reagents for HPV in human subjects and is
able to detect and differentiate between different strains in order
to distinguish "high risk" HPV taxon from "low risk" HPV taxon.
Accordingly, in some preferred embodiments, the present invention
provides beadsets which are able to distinguish between pluralities
of different HPV strains. As such, in one aspect, the analytes are
specific for a plurality of HPV taxons and the methods and/or
reagents are specific for the detection of nucleic acid or antigens
or antibodies which are specific for the plurality of HPV
taxons.
[0025] Even more preferred, nucleic acid primers or probes capable
of binding to a strain-specific portion of an HPV genome are
immobilized onto beads in each bead subset. Primers directed to
conserved regions within an HPV genome flanking a strain-specific
region are then used to amplify the HPV genome. Families of beads
or subsets of beads, each for any one strain of HPV are then used
to detect or distinguish the HPV strain.
[0026] Other aspects of the present invention are directed to
beadsets for detecting one or more strains of HPV and/or for
differentiating between two or more strains of HPV, wherein the
beadset comprises a plurality of families or subsets of beads
wherein:
[0027] (a) the beads of each subset are homogeneous with respect to
size;
[0028] (b) the beads within each subset are coupled to a nucleic
acid capture probe which is capable of binding to a HPV
strain-specific region of an HPV genome or, optionally, a control
nucleic acid sequence;
[0029] (c) the capture probe on each bead is labelled with the same
label with each subset of beads having a different fluorescent
intensity to create a heterogeneous mixture of beads based on
fluorescent intensity; and
[0030] (d) at least two subsets of beads are mixed together to
produce a beadset, wherein the subset identity and therefore the
strain of HPV is identifiable by flow cytometry based on size,
fluorescent intensity and sequence discrimination.
[0031] Other aspects of the present invention contemplate methods
for detecting and/or differentiating between two or more HPV
strains in a sample, comprising the steps of:
[0032] (a) contacting the sample with a beadset comprising a
plurality of families or subsets of beads wherein: [0033] (i) the
beads of each subset are homogeneous with respect to size; [0034]
(ii) the beads within each subset are coupled to a nucleic acid
capture probe which is capable of binding to a HPV strain-specific
region of an HPV genome or, optionally, a control nucleic acid
sequence; [0035] (iii) the capture probe on each bead is labelled
with the same label with each subset of beads having a different
fluorescent intensity to create a heterogeneous mixture of beads
based on fluorescent intensity; and [0036] (iv) at least two
subsets of beads are mixed together to produce a beadset, wherein
the subset identity and therefore the strain of HPV is identifiable
by flow cytometry based on size, intensity and sequence
discrimination;
[0037] (b) incubating said beadset with said sample for a time and
under conditions sufficient to allow said probes to bind to the HPV
genome amplified to generate a replicon comprising a
strain-specific region;
[0038] (c) detecting and/or differentiating the amplicons generated
in the sample which are bound to said beads to thereby identify or
distinguish between the two or more HPV strains.
[0039] In some preferred aspects, the beads within the beadsets are
distinguishable on the basis of size, the level of fluorescent
intensity, the type of fluorochrome and the reactant which is
capable of reacting with a specific analyte.
[0040] In other aspects, the present invention is directed to
beadsets for detecting a strain of HPV and/or for differentiating
between two or more strains of HPV, wherein the beadset comprises a
plurality of families or a plurality of subsets of beads
having:
[0041] (a) at least two subsets of beads, wherein each subset of
beads is physiochemically distinguishable from any other bead
subset based on at least size; or
[0042] (b) at least one subset of beads having at least two
families, wherein the beads in a bead subset are homogeneous in
size with respect to each other, and are physiochemically
distinguishable into two or more families of beads based on the
level of labelling each contains, or
[0043] (c) a combination of said families of beads and said subsets
of beads; and wherein:
[0044] the beads within each bead family of a subset are each
coupled to an optionally-labelled nucleic acid capture probe
capable of binding to a HPV strain-specific region of an HPV genome
or, optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and
[0045] each family of beads is specific for the detection of a
strain of HPV different from any other bead family in the beadset;
wherein said beadset is capable of identifying one or more specific
strains of HPV through analysis of bead size, fluorescent
intensity, or sequence discrimination of the at least one bead
family or bead subset, using flow cytometry.
[0046] The invention is also directed to part to methods for
preparing a beadset for differentiating between two or more strains
of HPV, the method comprising selecting a plurality of families or
subsets of beads based on size, fluorescent intensity, or both,
comprising providing:
[0047] (a) at least two subsets of beads, wherein each subset of
beads is physiochemically distinguishable from any other bead
subset based on at least size; or
[0048] (b) at least one subset of beads having at least two
families, wherein the beads in a bead subset are homogeneous in
size with respect to each other, and are physiochemically
distinguishable into two or more families of beads based on the
level of labelling each contains, or
[0049] (c) a combination of said families of beads and said subsets
of beads; and wherein:
[0050] the beads within each bead family of a subset are each
coupled to an optionally-labelled nucleic acid capture probe
capable of binding to a HPV strain-specific region of an HPV genome
or, optionally, to at least one of a control nucleic acid sequence,
provided that any nucleic acid capture probe or control nucleic
acid sequence is labelled with the same label as other labelled
capture probes or control nucleic acid sequence in the bead subset,
and that within any single subset of beads, each family of beads
thereof has a different fluorescent intensity; and
[0051] each family of beads is specific for the detection of a
strain of HPV different from any other bead family in the beadset;
wherein said beadset is capable of identifying one or more specific
strains of HPV through analysis of bead size, fluorescent
intensity, or sequence discrimination of the at least one bead
family or bead subset, using flow cytometry.
[0052] The methods of the present invention in relation to HPV
detection may be used to distinguish to between from 2 and 16
strains of HPV including between 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14, 15 and 16 strains. In view of the usefulness of a
control, the present invention therefore can use from 2-17
different beads or beadsets. In another embodiment, the beadset
comprises at least 16 subsets of beads for HPV strains 6, 11, 16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, and
typically a control beadset. Suitable capture probes are those
listed in Table 2.
[0053] It may be desirable to test for more than 16 strains of an
analyte. Thus, the present invention also includes bead sets with
2-30 different beads or bead sets, including 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
26, 27, 28, 29, and 30 beads or beadsets.
[0054] The present invention is directed in part to certain primer
pairs for use in any of the numerous PCR techniques for
amplification of nucleic acid sequences, wherein the forward and
reverse primers optionally have heels conjugated to the 5' terminus
of the primer. In certain embodiments the invention is directed to
oligonucleotide amplification primer pairs for targeting oncogenic
HPV, the forward primer of the pair, selected from the group
consisting of:
TABLE-US-00001 (SEQ ID NO: 1) TR TTT GTT ACT GTK GTD GAT ACY A;
(SEQ ID NO: 2) CAR YTR TTT GTT ACT GTK GTD GAT A; (SEQ ID NO: 3)
CAR YTR TTT GTT ACT GTK GTD GA; (SEQ ID NO: 4) AAY CAR YTR TTT GTT
ACT GTK GT; (SEQ ID NO: 5) TTT GTT ACT GTK GTD GAT ACY AC HCG; (SEQ
ID NO: 6) TTT GTT ACT GTK GTD GAT ACY AC HCG YAG; (SEQ ID NO: 7)
GTK GTD GAT ACY AC HCG YAG TAC and (SEQ ID NO: 8) GTD GAT ACY AC
HCG YAG TAC HAA;
and the reverse primer of the primer pair is selected from the
group consisting of:
TABLE-US-00002 (SEQ ID NO: 9) TGA AAA ATA AAY TGY AAA TCA TAT TCY
TCM MCA TG; (SEQ ID NO: 10) CAY ARY TGA AAA ATA AAY TGY AAA TC;
(SEQ ID NO: 11) TR CAY ARY TGA AAA ATA AAY TG; and (SEQ ID NO: 12)
TR CAY ARY TGA AAA ATA AA;
[0055] wherein the forward and reverse primers are each optionally
conjugated to a heel at the 5' terminus of the primer.
[0056] Determination of whether binding has occurred between an
analyte and a reactant present on a bead may be done using any
methodology which allows the differentiation between different
beads within the beadset. In certain particularly preferred
embodiments, the methods of differentiating between different beads
within the beadsets utilize flow cytometry.
[0057] The present invention further contemplates diagnostic kits
for use in accordance with the reagents and methods of the present
invention. In particular, the present invention extends to biochips
and the miniaturization of the solid phase components of the assay
to generate nanoassay reagents. In one embodiment, the bead set or
part thereof or other reagents are immobilized to a solid phase
such as a biochip. The biochip may also be regarded as a "biolab"
on which at least part of the assay is performed and/or results
recorded.
[0058] A list of abbreviations used herein is provided in Table
1.
TABLE-US-00003 TABLE 1 Abbreviations Abbreviation Description FITC
Fluorescein isothiocyanate HEX Hexachlorofluorescein HIV Human
Immunodeficiency Virus HPV Human Papilloma Virus JOE
7'-dimethoxyfluorescein PCR Polymerase chain reaction PE
Phycoerythrin PMT Photomultiplier tube QD Quantum dot TAMRA
Carboxytetramethylrhodamine TET Tetrachlorofluorescein TMR
Tetramethylrhodamine VRE Vancomycin resistant enterococci
[0059] A summary of the sequences used herein are shown in Table
2.
TABLE-US-00004 TABLE 2 Sequences (5' being on the left, 3' on the
right) PCR primer sequences Sequence SEQ ID NO: GP5+
TTTGTTACTGTGGTAGATACTA 13 C GP6+ GAA AAA TAA ACT GTA AAT 14 CAT ATT
C GP5d+ TTTKTTACHGTKGTDGATACYA 15 C GP6d+ GAAAHATAAAYTGYAADTCAT 16
AYTC GP5+ (5Phos) /5Phos/TTTGTTACTGTGGTAGAT 17 ACTAC GP6+ (5AmMC6)
/5AmMC6/GAA AAA TAA ACT 18 GTA AAT CAT AAT C GP5d+ (5Phos)
/5Phos/TTTKTTACHGTKGTDGAT 19 ACYAC GP6d+ (5AmMC6)
/5AmMC6/GAAAHATAAAYTGYA 20 ADTCATAYTC GP5d2+ TTT KTT ACH GTK GTD
GAT 21 ACH AC-3' T7aGP6d+ (HeelGP6d+) AAT TCT AAT ACG ACT CAC 22
TAT AGG GGA AAH ATA AAY TGY AAD TCA TAY TC GP5d3+ TTT GTT ACH GTD
GTD GAY 23 ACH AC T7aGP6D+*(HeelGP6d+) AAT TCT AAT ACG ACT CAC 24
TAT AGG GGA AAH ATA AAY TGY ARD TCA WAY TC GP5d2+ (5Phos)
/5Phos/TTT KTT ACH GTK GTD 25 GAT ACH AC-3' T7aGP6d+ (HeelGP6d+)
/5AmMC6/AAT TCT AAT ACG 26 (5AmMC6) ACT CAC TAT AGG GGA AAH ATA AAY
TGY AAD TCA TAY TC GP5d3+ (5Phos) 5Phos TTT GTT ACH GTD GTD 27 GAY
ACH AC T7aGP5D+* (5AmMC6) /5AmMC6/AAT TCT AAT ACG 28 ACT CAC TAT
AGG GGA AAH ATA AAY TGY ARD TCA WAY TC mlc1_95f GGC ACC CAG ACA ATA
CAC 29 T7amlc1_275r (HeelMLCR) AAT TCT AAT ACG ACT CAC 30 TAT AGG
GTA ACT TGA AGA GGT GAA GAA mlc1_95f (5Phos) /5Phos/GGC ACC CAG ACA
ATA 31 CAC T7amlc1_275r (HeelMLCR) /5AmMC6/AAT TCT AAT ACG 32
(5AmMC6) ACT CAC TAT AGG GTA AGT TGA AGA GGT GAA GAA GBHPVf1
/5Phos/caatcagc TR TTT GTT ACT 33 GTK GTD GAT ACY A GBHPVf2
/5Phos/acaat CAR YTR TTT GTT 34 ACT GTK GTD GAT A GBHPVf3
/5Phos/acaat CAR YTR TTT GTT 35 ACT GTK GTD GA GBHPVf3+
/5Phos/ggaacaat CAR YTR TTT 36 GTT ACT GTK GTD GA GBHPVf4
/5Phos/ggaac AAY CAR YTR TTT 37 GTT ACT GTK GT GBHPVf5
/5Phos/cagctt TTT GTT ACT GTK 38 GTD GAT ACY AC HCG GBHPVf6
/5Phos/cagctt TTT GTT ACT GTK 39 GTD GAT ACY AC HCG YAG GBHPVf7
/5Phos/attacc GTK GTD GAT ACY 40 AC HCG YAG TAC GBHPVf8
/5Phos/ctgtt GTD GAT ACY AC 41 HCG YAG TAC HAA GBHPVr1
/5AmMC6/actcactatagg TGA AAA 42 ATA AAY TGY AAA TCA TAT TCY TCM MCA
TG GBHPVr2 /5AmMC6/aatacgactcactatagg CAY 43 ARY TGA AAA ATA AAY
TGY AAA TC GBHPVr3 /5AmMC6/tctaatacgactcactatagg TR 44 CAY ARY TGA
AAA ATA AAY TG GBHPVr4 /5AmMC6/aattctaatacgactcactatagg 45 TR CAY
ARY TGA AAA ATA AA Capture probe sequences Sequence SEQ ID NO:
Probe 6: /5Acryd/AAT/iAmMC6T/AA AGG 46 GAG GAC AGC TAT GGA CAT CCG
TAA CTA CAT CTT CCA CAT ACA CCA A Probe 11: /5Acryd/AAT/iAmMC6T/AA
AGG 47 GAG GAC AGC TAT GGA CAT CTG TGT CTA AAT CTG CTA CAT ACA CTA
A Probe 16: /5Acryd/AAT/iAmMC6T/AA AGG 48 GAG GAC AGC TAT GGA CGT
CAT TAT GTG CTG CCA TAT CTA CTT CAG A Probe 18b:
/5Acryd/AAT/iAmMC6T/AA AGG 49 GAG GAC AGC TAT GGA CC TCC TGT ACC
TGG GCA ATA TGA TGC TAC CA Probe 31: /5Acryd/AAT/iAmMC6T/AA AGG 50
GAG GAC AGC TAT GGA CTG TTT GTG CTG CAA TTG CAA ACA GTG ATA C Probe
33: /5Acryd/AAT/iAmMC6T/AA AGG 51 GAG GAC AGC TAT GGA CTT TAT GCA
CAC AAG TAA CTA GTG ACA GTA C Probe 35: /5Acryd/AAT/iAmMC6T/AA AGG
52 GAG GAC AGC TAT GGA CGT CTG TGT GTT CTG CTG TGT CTT CTA GTG A
Probe 39: /5Acryd/AAT/iAmMC6T/AA AGG 53 GAG GAC AGC TAT GGA CTC TAC
CTC TAT AGA GTC TTC CAT ACC TTC T Probe 45: /5Acryd/AAT/iAmMC6T/AA
AGG 54 GAG GAC AGC TAT GGA CAC ACA AAA TCC TGT GCC AAG TAC ATA TGA
C Probe 51: /5Acryd/AAT/iAmMC6T/AA AGG 55 GAG GAC AGC TAT GGA CAG
CAC TGC CAC TGC TGC GGT TTC CCC AAC A Probe 52:
/5Acryd/AAT/iAmMC6T/AA AGG 56 GAG GAC AGC TAT GGA CTG CTG AGG TTA
AAA AGG AAA GCA CAT ATA A Probe56: /5Acryd/AAT/iAmMC6T/AA AGG 57
GAG GAC AGC TAT GGA CGT ACT GCT ACA GAA CAG TTA AGT AAA TAT G Probe
58b: /5Acryd/AAT/iAmMC6T/AA AGG 58 GAG GAC AGC TAT GGA CG CAC TGA
AGT AAC TAA GGA AGG TAC Probe 59: /5Acryd/AAT/iAmMC6T/AA AGG 59 GAG
GAC AGC TAT GGA CTC TAC TAC TTC TTC TAT TCC TAA TGT ATA C Probe 66:
/5Acryd/AAT/iAmMC6T/AA AGG 60 GAG GAC AGC TAT GGA CTA TTA ATG CAG
CTA AAA GCA CAT TAA CTA A Probe 68: /5Acryd/AAT/iAmAC6T/AA AGG 61
GAG GAC AGC TAT GGA CTC TAC TAC TAC TGA ATC AGC TGT ACC AAA T Probe
68b: /5Acryd/AAT/iAmMC6T/AA AGG 62 GAG GAC AGC TAT GGA CT CCA CTA
CTA CAG ACT CTA CTG TAC CA Probe MLC_Int: /5Acryd/AAT/iAmMC6T/AA
AGG 63 GAG GAC AGC TAT GGA CCA AAC ACA GAC ACA GAG AGA CCC ACA GAC
A Block Oligo Sequences* Sequence SEQ ID NO: block6/4: ##STR00001##
64 ##STR00002## block11/4: ##STR00003## 65 ##STR00004## block16/4:
##STR00005## 66 ##STR00006## block18b/4: ##STR00007## 67
##STR00008## block31/4: ##STR00009## 68 ##STR00010## block33/4:
##STR00011## 69 CAT AAA block35/4: ##STR00012## 70 GAC block39/4:
##STR00013## 71 AGA block45/4: ##STR00014## 72 TGT block51/4:
##STR00015## 73 AGT GCT block52/4: ##STR00016## 74 GCA block56/4:
##STR00017## 75 TAC block58b/4: ##STR00018## 76 block59/4:
##STR00019## 77 AGA block66/4: ##STR00020## 78 ATA block68/4:
##STR00021## 79 AGA block68b/4: ##STR00022## 80 blockMLC/4:
##STR00023## 81 TTG Signal Oligos Sequences Sequence SEQ ID NO: HPV
signal a: /5AmMC6/TTT TTT CAT GKK GAR 82 GAR TAT GA/3Phos/
HPVsignal b: /5AmMC6/TTT TTT CAT GKK GAR 83 GAR TAT/3Phos/ MLC
signal a: /5AmMC6/TTT TTT ACA GAC ACA 84 GAC AAC/3Phos/ MLCsignal
b: /5AmMC6/TTT TTT ACA GAC ACA 85 GAC AAC A/3Phos/ MLCsignal c:
/5AmMC6/TTT TTT ACA GAC ACA 86 GAC AAC AC/3Phos/ *Wherein the
shaded bases correspond to the differences.
[0060] The following variables are used herein:
[0061] "K" is a variable for G or T;
[0062] "H" is a variable for the nucleotides T, A, or C;
[0063] "M" is a variable for the nucleotides A or C;
[0064] "Y" is a variable for the nucleotides T or C;
[0065] "R" is a variable for the nucleotides A or G;
[0066] "W" is a variable for the nucleotides A or T;
[0067] "D" is a variable for the nucleotides A, T, or G;
[0068] 3Phos is a 3' phosphate group;
[0069] 5Phos is a 5' phosphate group; and,
[0070] 5AmMC6 is a 5' H.sub.2N--(CH.sub.2).sub.6-- group attached
via a phosphate group.
BRIEF DESCRIPTION OF THE FIGURES
[0071] FIG. 1 is a graphical representation showing a schematic of
an example of a DNA extraction protocol used in the HPV diagnostic
method.
[0072] FIG. 2 is a graphical representation showing a PCR protocol
that can be used to amplify HPV and human DNA from a DNA sample.
GP5+ and GP6+ refer to universal HPV primers which bind to
conserved sequences (Y) in HPV and generate an amplicon which
comprises a region which is variable between HPV strains
(X.sub.1-16). Primers LC1_F and LC1_R amplify a human genomic DNA
region (Z) which serves as a control in the later hybridization
steps. Primers GP6+ and LC1_R comprise a fluorescent label which is
incorporated into the amplicon generated.
[0073] FIG. 3 is a graphical representation showing the
differentiation of microspheres on the basis of size. Six clusters
corresponding to microspheres comprising diameters of 3.0 .mu.m,
3.5 .mu.m, 4.1 .mu.m, 5.0 .mu.m, 5.6 .mu.m and 6.8 .mu.m are
shown.
[0074] FIG. 4 is a graphical representation showing the
differentiation of microspheres of the same size on the basis of
fluorescent label intensity. TMR relative intensities of 0%, 4%,
20% and 100% could be clearly distinguished.
[0075] FIG. 5 is a schematic diagram showing an example of the
binding agents that can be used in the array. The array comprises
microspheres comprising diameters of 3.0 .mu.m, 3.5 .mu.m, 4.1
.mu.m, 5.0 .mu.m, 5.6 .mu.m and 6.8 .mu.m and fluorescent label
signal intensities of 0%, 4%, 20% and 100%. In the case of the
smaller bead sizes, i.e., 3.0 .mu.m, 3.5 .mu.m, and 4.1 .mu.m, TMR
intensities of 0% and 100% were used; for the 5.0 .mu.m
microspheres TMR intensities of 0%, 20% and 100% were used; and for
the largest microspheres, the 5.6 .mu.m and 6.8 .mu.m diameter, all
signal intensities were used.
[0076] FIG. 6 shows an example of a headset of the present
invention.
[0077] FIG. 7 is a graphical representation showing an example of
the binding agent array to which an amplicon has bound. The results
show binding to the viral conserved sequence, Y, the human control
sequence Z, and the viral strain-specific sequence X.sub.16.
[0078] FIG. 8 is a photographical representation showing agarose
gel electrophoretic analysis of PCR products following
amplification from HPV type-specific insert-containing plasmids
using various combinations of primers.
DETAILED DESCRIPTION OF THE INVENTION
[0079] The present invention provides assays and reagents including
biochips which enable the detection of one or more analytes and/or
to differentiate between members within a class of analytes. In
particular, analytes are identified or distinguished by methods of
multiplexing analysis based on the properties of the analytes and
of the assay components. The diagnostic and detection assays and
reagents of the present invention have particular application in
the diagnosis of pathogen infections in multicellular eukaryotic
subjects. In one particular embodiment, the present invention
provides a diagnostic assay for HPV in human subjects and is able
to differentiate between HPV taxons in order to distinguish "high
risk" HPV infections from "low risk" HPV infections. Furthermore,
the present invention also provides methods of diagnosing or
assessing the risk of development of a disease associated with an
infection by an analyte in a multicellular eukaryotic subject
including, inter alia, cervical cancer in a human subject.
[0080] It is to be understood that unless otherwise indicated, the
subject invention is not limited to specific diagnostic or assay
protocols, as such may vary. It is also to be understood that the
terminology used herein is for the purpose of describing particular
embodiments only and is not intended to be limiting.
[0081] It must be noted that, as used in the subject specification,
the singular forms "a", "an" and "the" include plural aspects
unless the context already dictates otherwise. Thus, for example,
reference to "an analyte" includes a single analyte as well as two
or more analytes; a "physiochemically distinguishable substrate"
includes a single substrate as well as two or more substrates;
reference to "a target" includes a single target, as well as two or
more targets; reference to "an amplification" includes a single
amplification, as well as multiple amplification steps; reference
to "the amplicon" includes a single or multiple or complex
amplicons; and so forth.
[0082] Accordingly, in one aspect, the present invention provides
headsets which are capable of detecting, and/or differentiating
between two or more analytes in a sample, said beadsets
comprising:
[0083] (a) the beads of each subset are homogeneous with respect to
size;
[0084] (b) the beads within each subset are coupled to a reactant
that will specifically react with a given analyte of interest in a
sample to be tested;
[0085] (c) the reactant on each bead is labelled with the same
label with each subset of beads having a different fluorescent
intensity to create a heterogeneous mixture of subsets of beads
based on fluorescent intensity; and
[0086] (d) at least two subsets of beads are mixed together to
produce a beadset, wherein the subset identity and therefore the
reactant to which the bead has been coupled is identifiable by flow
cytometry based on size, fluorescent intensity and analyte
discrimination.
[0087] In some embodiments, the reactants may be further
differentially labelled to create additional subpopulations of
beads based on the incorporation of different fluorochromes.
[0088] In other embodiments, the present invention provides methods
or beadsets for the detection and/or differentiation of an
analyte.
[0089] In certain preferred aspects, the methods or beadsets of the
present invention are able to detect and/or differentiate
pathogenic analytes.
[0090] The present invention also provides methods for detecting
and/or differentiating between one or more analytes in a sample
comprising the steps of:
[0091] (a) contacting the sample with a beadset specific for the
analytes of interest;
[0092] (b) incubating said beadset with said sample for a time and
under conditions sufficient to allow said analyte(s) in said sample
to react specifically with a reactant on a bead within said
beadset; and
[0093] (c) detecting and/or differentiating analytes in the sample
which are bound to a reactant on said bead.
[0094] As used herein, the term "pathogenic analyte" refers to a
microorganism or virus which putatively infects, colonizes or has
otherwise contaminated the sample. Exemplary pathogen analytes
include viruses, bacteria, fungi and eukaryotic microorganisms. In
a preferred embodiment, "analyte" includes a microorganism or virus
which infects a multicellular organism such as an animal or plant.
Accordingly, in some embodiments the pathogenic analytes may be
regarded as an animal or plant pathogen. However, the present
invention encompasses the detection and differentiation of
non-pathogenic analyte which colonize multicellular organisms such
as microbial symbionts of animals (e.g., Lactobacillus spp.,
ruminant bacteria), microbial symbionts of insects (e.g.,
Streptomyces spp., Wolbachia spp.), microbial symbionts of sponges
(e.g., green algae, dinoflagellates, cyanobacteria) and the like;
endophytes of plants (e.g., Mycorrhiza, Rhizobium spp., Frankia
spp., Streptomyces spp.); and the like. Furthermore, the analyte
may be an analyte which is not associated with a multicellular
organism. Such analytes include bacteria, fungi, viruses, protists,
nematodes and the like which colonize particular environments
including "natural" environments such as soil, oceans, fresh water,
ice, rock, hydrothermal vents and air; health care environments
including hospitals, hospital equipment, surgical equipment, health
care staff garments and the like; "industrial" environments
including manufacturing facilities, pharmaceutical facilities,
breweries, wineries and the like; "laboratory" environments
including fermenters, cultures, benches, equipment and the
like.
[0095] Accordingly, samples contemplated by the present invention
include industrial samples such as air, water, and soil, and the
like, and biological samples such as blood, serum, saliva, faeces,
urine, tissue fluid, semen, exudate, pus, respiratory fluid and
mucus and swabs from topical sores, cancers and lesions. In
addition, a sample may be an extraterrestrial sample such as from a
meteorite or on another planet. In regards to the latter, the assay
of the present invention may be adapted for use on an
interplanetary remote vehicle for testing of soil or dust or ice
samples or for testing core material in a planet.
[0096] In some preferred embodiments, the analyte comprises a
bacterium, fungus, virus and/or eukaryotic parasite which infects
an animal subject. "Animal subjects" contemplated herein include
any animal, preferably a mammal and more preferably a primate
including a lower primate and even more preferably, a human. For
convenience, an "animal" also specifically includes livestock
species such as cattle, horses, sheep, pigs, goats and donkeys as
well as laboratory animals including mice, rats, rabbits, guinea
pigs and hamsters.
[0097] Exemplary human analytes which may be detected using the
reagents and methods of the present invention include viruses such
Human papilloma virus (HPV), coronaviruses including the SARS
virus, influenza viruses, avian flue virus, HIV including HIV-1,
HIV-II or HLTV-IV, Lentiviruses in general, hepatitis viruses and
the like, the pathogenic agents of sexually transmitted diseases
such as Chlamydia, Gonorrhoea, Mycoplasma spp. and Syphilis;
Food-borne pathogens such as Listeria spp., Salmonella spp., E.
coli (particularly E. coli HO 567), Shigella spp., Brucella spp.,
Staphylococcus aureus; Nosicomial pathogens such as S. aureus
including Methicillin-Resistant S. Aureus (MRSA) and enterococci
including Vancomycin Resistant Enterococci (VRE); Environmentally
acquired pathogens such as Legionella spp., Giardia spp.,
Crytospiridium spp., Bacillus anthacis (anthrax) and the like.
[0098] In other aspects, the sample in which the analyte is
detected is preferably a sample derived from a multicellular
subject which is putatively infected or colonized by the analyte.
Therefore, in one aspect, the sample is preferably a "biological
sample". Exemplary biological samples which in no way limit the
present invention include tissue or cell samples such as cell
scapes, biopsies and the like and body fluid samples including
blood, urine, lymph, amniotic fluid, cerebrospinal fluid and the
like.
[0099] In certain other aspects, the methods of the present
invention are also applicable to the detection of an "analyte" in a
sample which is not exclusively derived from a multicellular
eukaryotic organism. As such, the present invention extends to
detecting, and/or differentiating between, one or more particular
taxons or strains of analytes in samples such as environmental
samples (including air, water and soil samples), industrial
samples, laboratory samples and the like. For example, the methods
of the present invention may be used to assess the prokaryotic
microflora, eukaryotic microflora and or viral load of a soil,
water or air sample or a sample derived from a man-made object or
surface.
[0100] In some particularly preferred embodiments of the present
invention, the analyte to be detected is HPV or a strain thereof
and the sample is preferably a biological sample derived from a
human subject. In a further preferred embodiment, the biological
sample comprises one or more cells of the subject, blood or urine.
Most preferably, the biological sample comprises cervical cells
collected from the subject. HPV is described in detail by Gearhart
et al. which is reproduced in part below. HPVs produce epithelial
tumors of the skin and mucous membranes. Over 100 HPV types have
been detected, and the genomes of almost 70 have been sequenced
completely. The current classification system, which is based on
similarities in their genomic sequences, generally correlates with
the 3 categories used to describe HPV clinically: anogenital and/or
mucosal, nongenital cutaneous, and epidermodysplasia verruciformis
(EV). A database of HPV genomic sequences and a phylogenic tree are
available via the Internet at HPV Sequence Database.
[0101] The mucosal HPV infections are classified further as latent
(asymptomatic), subclinical, or clinical. Clinical lesions are
grossly apparent, whereas latent infections are detected only by
tests for viral DNA. Subclinical lesions are identified by
application of 5% acetic acid and inspection under magnification.
Most HPV infections are latent; clinically apparent infections
usually result in warts rather than malignancies.
[0102] HPV types 6 and 11 are typically labelled as low risk
because infection with these types has low oncogenic potential and
usually results in the formation of condylomata and low-grade
precancerous lesions. HPV types 16 and 18 have emerged as the
high-risk types of HPV because they are responsible for most
high-grade intraepithelial lesions that may progress to carcinomas,
particularly those in the anogenital and/or mucosal category.
[0103] HPV infection alone does not cause malignant transformation
of infected tissue. Cofactors, such as tobacco use, ultraviolet
radiation, pregnancy, folate deficiency, and immune suppression
have been implicated in this process. Table 3 lists a variety of
diseases and the associated HPV subtypes.
TABLE-US-00005 TABLE 3 Diseases and Associated HPV Subtypes HPV
Type Nongenital Cutaneous Disease Common warts (verrucae vulgaris)
1, 2, 4, 26, 27, 29, 41, 57, 65 Plantar warts (myrmecias) 1, 2, 4,
63 Flat warts (verrucae plana) 3, 10, 27, 28, 38, 41, 49 Butcher's
warts (common warts of people 1, 2, 3, 4, 7, 10, 28 who handle
meat, poultry, and fish) Mosaic warts 2, 27, 57 Ungual squamous
cell carcinoma 16 Epidermodysplasia verruciformis (benign) 2, 3,
10, 12, 15, 19, 36, 46, 47, 50 Epidermodysplasia verruciformis 5,
8, 9, 10, 14, 17, 20, 21, 22, (malignant or benign) 23, 24, 25, 37,
38 Nonwarty skin lesions 37, 38 Nongenital Mucosal Disease
Respiratory papillomatosis 6, 11 Squamous cell carcinoma of the
lung 6, 11, 16, 18 Laryngeal papilloma 6, 11, 30 Laryngeal
carcinoma 16, 18 Maxillary sinus papilloma 57 Squamous cell
carcinoma of the sinuses 16, 18 Conjunctival papillomas 6, 11
Conjunctival carcinoma 16 Oral focal epithelial hyperplasia 13, 32
(Heck disease) Oral carcinoma 16, 18 Oral leukoplakia 16, 18
Squamous cell carcinoma of the esophagus 16, 18 Anogenital Disease
Condylomata acuminata 6, 11, 30, 42, 43, 44, 45, 51, 52, 54
Bowenoid papulosis 16, 18, 34, 39, 42, 45 Bowen disease 16, 18, 31,
34 Giant condylomata 6, 11 (Buschke-Lowenstein tumors) Unspecified
intraepithelial neoplasia 30, 34, 39, 40, 53, 57, 59, 61, 62, 64,
66, 67, 68, 69 Low-grade intraepithelial neoplasia 6, 11, 43
Intermediate intraepithelial neoplasia 31, 33, 35, 42, 44, 45, 51,
52 High-grade intraepithelial neoplasia 16, 18, 56, 58 Carcinoma of
vulva 6, 11,16, 18 Carcinoma of vagina 16 Carcinoma of cervix 16,
18, 31 Carcinoma of anus 16, 31, 32, 33 Carcinoma in situ of penis
16 (erythroplasia of Queyrat) Carcinoma of penis 16, 18
[0104] Papillomaviruses are highly species specific and do not
infect other species, even under laboratory conditions. Humans are
the only known reservoir for HPV.
[0105] Papillomaviruses are nonenveloped viruses of icosahedral
symmetry with 72 capsomeres that surround a genome containing
double-stranded circular DNA with approximately 8000 base
pairs.
[0106] Papillomaviruses are thought to have two modes of
replication, i.e., stable replication of the episomal genome in
basal cells and runaway, or vegetative, replication in more
differentiated cells to generate progeny virus. Although all cells
of a lesion contain the viral genome, the expression of viral genes
is tightly linked to the state of cellular differentiation. Most
viral genes are not activated until the infected keratinocyte
leaves the basal layer. Production of virus particles can occur
only in highly differentiated keratinocytes; therefore, virus
production only occurs at the epithelial surface where the cells
are ultimately sloughed into the environment.
[0107] HPV lesions are thought to arise from the proliferation of
infected basal keratinocytes. Infection typically occurs when basal
cells are exposed to infectious virus through a disturbed
epithelial barrier as would occur during sexual intercourse or
after minor skin abrasions. HPV infections have not been shown to
be cytolytic, rather viral particles are released as a result of
degeneration of desquamating cells. Furthermore, the HPV virus can
survive for many months and at low temperatures without a host.
[0108] Virus multiplication is generally confined to the nucleus.
Consequently, infected cells usually exhibit a high degree of
nuclear atypia. Koilocytosis (from the Greek koilos, meaning empty)
describes a combination of perinuclear clearing (halo) with a
pyknotic or shrunken (rasinoid) nucleus and is a characteristic
feature of productive papillomavirus infection.
[0109] The HPV genome exists as a circular episomal DNA separate
from the host cell nucleus in benign or low-risk HPV lesions, such
as those typically associated with HPV types 6 and 11. The genomes
of high-risk HPV types 16 and 18 are typically integrated into the
host cell DNA in malignant lesions. The present invention, however,
extends to any strain of HPV including but not limited to strains
6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Integration of the viral genome into the host cell genome is
considered a hallmark of malignant transformation. HPV proteins E6
and E7 of high-risk serotypes have been shown to inactivate the
host's tumor suppressor proteins p53 and Rb, thereby resulting in
unregulated host cell proliferation and malignant
transformation.
[0110] Therefore, in other aspects, the present invention provides
methods for detecting, and/or differentiating between, one or more
particular strains of HPV in a biological sample, said methods
comprising the steps of: [0111] (i) obtaining a biological sample
which putatively comprises HPV from a human subject; [0112] (ii)
isolating nucleic acid from said sample; [0113] (iii) amplifying
the nucleic acid from said sample using primers which generate an
amplicon which is distinct for each strain of HPV; [0114] (iv)
optionally amplifying a control nucleic acid sequence; [0115] (v)
effecting labelling of the amplicon(s) recited at steps (iii)
and/or (iv); [0116] (vi) hybridizing the labelled amplicon(s) to a
beadset coated with reactants wherein each member of the beadset
comprises a nucleic acid molecule having complementarity to a
nucleotide sequence of a particular strain of HPV or a control
nucleotide sequence, bound or otherwise associated with a
physiochemically distinguishable bead; and [0117] (vii) determining
to which of the reactants an amplicon has bound; wherein the
association of an amplicon with a particular reactant is indicative
of the presence of a particular strain of HPV in the sample.
[0118] In yet other aspects, the hybridizing occurs in the presence
of at least one signal oligonucleotide sequence.
[0119] In still other aspects, the hybridizing occurs in the
presence of at least one blocking oligonucleotide sequence. [0120]
The present invention enables the detection of amplified HPV DNA
or, with the use of a reverse transcriptase, corresponding RNA.
Hence, the present invention contemplates beads with RNA or DNA or
chemical analogs thereof.
[0121] The methods of the present invention are predicated, in
part, on detecting and/or differentiating between one or more
particular strains of a subject analyte in a sample. Reference
herein to "particular strains of a subject analyte" includes any
variants of the species or taxon of the analyte. Examples of
"strains" of an analyte include sub-species of the analyte,
variants of the analyte with differing levels of virulence,
variants of the analyte which indicate different prognoses when
infecting or colonizing a host, biochemical variants of the analyte
and the like.
[0122] In some preferred embodiments, the methods of the present
invention may be adapted to detecting and/or differentiating
between particular strains of HPV which are associated with higher
risk or higher oncogenic potential in humans (high risk strains)
and those which are associated with lower carcinoma risk or low
oncogenic potential (low risk strains). Accordingly, the term "high
risk" strain of HPV includes any strain of HPV which is associated
with the development of carcinoma, including cervical cancer, in
human subjects. As indicated above, exemplary high risk strains of
HPV, which in no way limits the invention, include HPV 16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Suitable capture
probes on the beads for these strains of HPV are shown in Table 2.
The term "probe" and "primer" may be used interchangeably in this
context. "Low risk" strains of HPV include those which are not
associated or only weakly associated with increased risk of
carcinoma in human subjects. Typically, the low-risk strains of HPV
are the wart-forming strains, including HPV 6 and HPV 11.
[0123] The beads of the present invention are coupled to reactants
which will specifically interact with a given analyte of interest
within a sample. In some aspects, the reactants of the present
invention are nucleic acids and the analytes within the sample
which specifically react with the reactant are also nucleic
acids.
[0124] Hence, this aspect of the subject invention uses primers
which are directed to conserved regions of a strain of HPV but
which flank strain-specific genomic sequences. The strain-specific
sequences are referred to as "variable" sequences since they vary
between strains compared to the conserved sequences which are
constant between strains. Upon amplification, the amplicons are put
into contact with subsets of beads in the beadset wherein each bead
of each subset carries a capture nucleic acid primer or probe
capable of hybridizing to the strain-specific amplicons.
Multiplexing using bead size, fluorescence intensity and DNA
binding specificity enables identification, sorting and
distinguishing of HPV strains.
[0125] Accordingly, other aspects of the present invention
contemplates beadsets for detecting one or more strains of HPV
and/or for differentiating between two or more strains of HPV,
wherein the beadset comprises a plurality of families or subsets of
beads wherein:
[0126] (a) the beads of each subset are homogeneous with respect to
size;
[0127] (b) the beads within each subset are coupled to a nucleic
acid capture probe which is capable of binding to a HPV
strain-specific region of an HPV genome or, optionally, a control
nucleic acid sequence;
[0128] (c) the capture probe on each bead is labelled with the same
label with each subset of beads having a different fluorescent
intensity to create a heterogeneous mixture of beads based on
fluorescent intensity; and
[0129] (d) at least two subsets of beads are mixed together to
produce a beadset, wherein the subset identity and therefore the
strain of HPV is identifiable by flow cytometry based on size,
fluorescent intensity and sequence discrimination.
[0130] Still other aspects of the present invention contemplate a
methods for detecting and/or differentiating between two or more
HPV strains in a sample, comprising the steps of:
[0131] (a) contacting the sample with a beadset comprising a
plurality of families or subsets of beads wherein: [0132] (i) the
beads of each subset are homogeneous with respect to size; [0133]
(ii) the beads within each subset are coupled to a nucleic acid
capture probe which is capable of binding to a HPV strain-specific
region of an HPV genome or, optionally, a control nucleic acid
sequence; [0134] (iii) the capture probe on each bead is labelled
with the same label with each subset of beads having a different
fluorescent intensity to create a heterogeneous mixture of beads
based on fluorescent intensity; and [0135] (iv) at least two
subsets of beads are mixed together to produce a beadset, wherein
the subset identity and therefore the strain of HPV is identifiable
by flow cytometry based on size, fluorescent intensity and sequence
discrimination;
[0136] (b) incubating said beadset with said sample for a time and
under conditions sufficient to allow said primers to bind to the
HPV genome amplified to generate a replicon comprising a
strain-specific region;
[0137] (c) detecting and/or differentiating the amplicons generated
in the sample which are bound to said beads to thereby identify or
distinguish between the two or more HPV strains.
[0138] The amplicons to which the nucleic acid capture probes are
specific may also be labelled with a fluorescent reporter
molecule.
[0139] Nucleic acids may be isolated from the subject sample using
any method which is convenient with regard to the nature of the
sample itself and the analyte. As used herein, the term "nucleic
acid" refers to DNA and/or RNA. Typically, DNA is isolated,
although under some circumstances which would be evident to one of
skill in the art, it may be more preferable to isolate RNA, for
example, when the analyte of interest is an RNA virus. If RNA is
isolated, the RNA may be amplified, or the RNA may be reverse
transcribed into cDNA using standard methods, for subsequent
amplification and analysis.
[0140] Preferably, the "nucleic acid" is DNA. DNA may be isolated
from the sample using any convenient means. For example, in the
case of a virus such as HPV in a human cell sample, guanidine or a
functionally equivalent agent may be used to lyse the cells. An
exemplary guanidine-based method for cell lysis and DNA extraction
is the method of Nelson and Krawetz (Anal. Biochem. 207(1):97-201,
1992). Guanidine-based lysis solutions are also commercially
available from suppliers such as Qiagen, e.g., QIAamp, PAXgene, and
the like. However, methods of lysis may change depending on the
nature of the sample and analyte. For example, for the detection of
an analyte in an environmental sample such as a soil or sediment
sample, a glass-bead based cell lysis system may be more
appropriate, such as the method of Kuske et al. (Appl. Environ.
Microbiol. 64(7):2463-2472, 1998). In any event, the appropriate
lysis protocol for a given analyte and sample would be readily
determined by one of ordinary skill in the art with no undue
experimentation.
[0141] After lysis of the cells, the DNA may be purified by any
convenient means which would be readily evident to one of skill in
the art (e.g., see commercially available kits hereinabove). In
certain preferred embodiments of the invention, the DNA is purified
using a limiting amount of a DNA binding agent such as, but not
limited to, silica. By using a limiting amount of the DNA binding
agent, a uniform amount of DNA may be isolated from different
samples as the amount of DNA recovered in each case is equal to the
maximum amount of DNA that can be bound by the limiting amount of
DNA binding agent. The DNA bound to the DNA binding agent may then
be recovered or eluted from the DNA binding agent using any
convenient means.
[0142] Although DNA is a preferred nucleic acid, RNA may also be
isolated from the sample using any standard RNA isolation protocol.
RNA isolation typically involves a cell disruption step and an RNA
isolation step. Exemplary cell disruption techniques which are
suitable for the isolation of RNA include those presented in Ambion
Technical Bulletin #183. Furthermore, a range of exemplary RNA
isolation kits which are suitable for a range of sample types.
However, it should be understood that the present invention is not
in any way limited by these specific methods and kits for RNA
isolation and purification and the present invention is compatible
with any RNA isolation methods which would be evident to one of
skill in the art.
[0143] The beadset may comprise, in relation to HPV detection as
many subsets of beads as strains of HPV. Hence, the assay may
employ 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 subsets
of beads each for HPV strains 6, 11, 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66 and 68. Additional beads may also be used
for controls. Suitable capture probes are disclosed in Table 2.
[0144] Hence, other aspects of the present invention are directed
to beadsets for detecting one or more strains of HPV and/or for
differentiating between two or more strains of HPV, wherein the
beadset comprises a plurality of families or subsets of beads
wherein:
[0145] (a) the beads of each subset are homogeneous with respect to
size;
[0146] (b) the beads within each subset are coupled to a nucleic
acid capture probe selected from the list in Table 2 that is
capable of binding to a HPV strain-specific region of an HPV genome
or, optionally, a control nucleic acid sequence;
[0147] (c) the capture probe on each bead is labelled with the same
label with each subset of beads having a different fluorescent
intensity to create a heterogeneous mixture of beads based on
fluorescent intensity; and
[0148] (d) at least two subsets of beads are mixed together to
produce a beadset, wherein the subset identity and therefore the
strain of HPV is identifiable by flow cytometry based on size,
fluorescent intensity and sequence discrimination.
[0149] Still a further aspect of the present invention contemplates
methods for detecting and/or differentiating between two or more
HPV strains in a sample, comprising the steps of:
[0150] (a) contacting the sample with a beadset comprising a
plurality of families or subsets of beads wherein: [0151] (i) the
beads of each subset are homogeneous with respect to size; [0152]
(ii) the beads within each subset are coupled to a nucleic acid
capture probe is selected from the list in Table 2 that is capable
of binding to a HPV strain-specific region of an HPV genome or,
optionally, a control nucleic acid sequence; [0153] (iii) the
capture probe on each bead is labelled with the same label with
each subset of beads having a different fluorescent intensity to
create a heterogeneous mixture of beads based on fluorescent
intensity; and [0154] (iv) at least two subsets of beads are mixed
together to produce a beadset, wherein the subset identity and
therefore the strain of HPV is identifiable by flow cytometry based
on size, fluorescent intensity and sequence discrimination;
[0155] (b) incubating said beadset with said sample for a time and
under conditions sufficient to allow said probes to bind to the HPV
genome amplified to generate a replicon comprising a
strain-specific region; and
[0156] (c) detecting and/or differentiating the amplicons generated
in the sample which are bound to said beads to thereby identify or
distinguish between the two or more HPV strains.
[0157] Accordingly, the beadsets may comprise 2, 3, 4, 5, 6, 7, 8,
10, 11, 12, 13, 14, 15, 16 subsets of beads each with one of a
nucleic acid molecule selected from the listing in Table 2.
Reference to these HPV strain-specific sequences in Table 2
includes nucleic acid molecules having at least 90% identity to
these sequences or capable of hybridizing thereto or their
complementary forms under low stringency conditions. Reference to
at least 90% includes 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 and
100%.
[0158] The methods of the present invention rely, in part, on
amplifying a nucleic acid from a sample using primers that bind to
conserved sequences among different strains of the subject analyte,
but which generate an amplicon which comprises a distinct
nucleotide sequence for each strain of the analyte. In effect, the
primers used in the present invention bind to sequences which are
conserved among strains of the subject analyte which flank regions
that are at least partially non-conserved or polymorphic between
strains. Schematically, the amplified region in the analyte has the
general structure of:
C--X--C'
wherein:
[0159] C is a nucleotide sequence which is conserved among two or
more strains of the analyte and is the binding site of the
"forward" primer;
[0160] X is a nucleotide sequence, part or all of which comprises
variation between different strains of the analyte;
[0161] C' is a nucleotide sequence which is conserved among two or
more strains of the analyte and is the binding site of the
"reverse" primer.
[0162] In certain embodiments it is desirable to incorporate heels
into one or more of the primers to modify the nucleic acid
amplification process. Preferably, these heels are conjugated to
the 5' terminus of a primer. More preferably, one ore more heels
are optionally further conjugated to a 5 Phos or 5AmMC6 moiety at
the heel's 5' terminus. In certain preferred embodiments, the heels
conjugated to forward primers are selected from: caatcagc, acaat,
ggaac, cagctt, attacc, and ctgtt, more preferably acaat and ctgtt.
In other preferred embodiments, the heels conjugated to reverse
primers are selected from:
TABLE-US-00006 (SEQ ID NO: 87) actcactatagg, (SEQ ID NO: 88)
aatacgactcactatagg, (SEQ ID NO: 89) tctaatacgactcactatagg,_ and
(SEQ ID NO: 90) aattctaatacgactcactatagg more preferably (SEQ ID
NO: 87) actcactatagg and (SEQ ID NO: 89) tctaatacgactcactatagg.
[0163] In certain embodiments related to oligonucleotide
amplification primer pairs for targeting oncogenic HPV, the forward
primer of a primer pair is selected from the group consisting
of:
TABLE-US-00007 (SEQ ID NO: 33) /5Phos/caatcagc TR TTT GTT ACT GTK
GTD GAT ACY A; (SEQ ID NO: 34) /5Phos/acaat CAR YTR TTT GTT ACT GTK
GTD GAT A; (SEQ ID NO:35) /5Phos/acaat CAR YTR TTT GTT ACT GTK GTD
GA; (SEQ ID NO: 37) /5Phos/ggaac AAY CAR YTR TTT GTT ACT GTK GT;
(SEQ ID NO: 38) /5Phos/cagctt TTT GTT ACT GTK GTD GAT ACY AC HCG;
(SEQ ID NO: 39) /5Phos/cagctt TTT GTT ACT GTK GTD GAT ACY AC HCG
YAG; (SEQ ID NO: 40) /5Phos/attacc GTK GTD GAT ACY AC HCG YAG TAC;
and (SEQ ID NO: 41) /5Phos/ctgtt GTD GAT ACY AC HCG YAG TAC
HAA;
and the reverse primer of a primer pair is selected from the group
consisting of:
[0164] /5AmMC6/actcactatagg TGA AAA ATA AAY TGY AAA TCA TAT TCY TCM
MCA TG (SEQ ID NO: 42);
[0165] /5AmMC6/aatacgactcactatagg CAY ARY TGA AAA ATA AAY TGY AAA
TC (SEQ ID NO: 43);
[0166] /5AmMC6/tctaatacgactcactatagg TR CAY ARY TGA AAA ATA AAY TG
(SEQ ID NO: 44); and
[0167] /5AmMC6/aattctaatacgactcactatagg TR CAY ARY TGA AAA ATA AA
(SEQ ID NO: 45). As shown, a primer is indicated in capital letters
and an optional heel in each instance is shown in underlined lower
case letters. Preferably, the forward primer of a primer pair is
selected from: /5Phos/acaat CAR YTR TTT GTT ACT GTK GTD GA (SEQ ID
NO: 35) and /5Phos/ctgtt GTD GAT ACY AC HCG YAG TAC HAA (SEQ ID NO:
41). In other preferable embodiments, the reverse primer of a
primer pair is selected from /5AmMC6/actcactatagg TGA AAA ATA AAY
TGY AAA TCA TAT TCY TCM MCA TG (SEQ ID NO: 42) and
/5AmMC6/tctaatacgactcactatagg TR CAY ARY TGA AAA ATA AAY TG (SEQ ID
NO: 44).
[0168] In certain aspects of the invention, the primers incorporate
a non-primer binding region 5' extraneous nucleotide sequence
conjugated to the 5' end of a 3' template binding primer region.
The 5' extraneous nucleotide sequence is conveniently referred to
herein as a "heel," "heel clamp," "heel sequence," or "extraneous
heel sequence," but this is not in any way intended to be limiting
on the subject invention.
[0169] In certain preferred embodiments, at least one of the
forward and reverse primers is conjugated to a heel at the 5'
terminus of the primer. Preferably, when the forward primer is
conjugated to a heel at the 5' terminus of the forward primer, the
forward primer heel is selected from the group consisting of:
[0170] CAATCAGC, ACAAT, GGAACAAT, GGAAC, CAGCTT, ATTACC, CTGTT,
/5Phos/CAATCAGC, /5Phos/ACAAT, /5Phos/GGAACAAT, /5Phos/GGAAC,
/5Phos/CAGCTT, 5Phos/ATTACC, and /5Phos/CTGTT. Preferably when the
reverse primer is conjugated to a heel at the 5' terminus of the
reverse primer, the reverse primer heel is selected from the group
consisting of:
[0171] ACTCACTATAGG (SEQ ID NO: 87), AATACGACTCACTATAGG (SEQ ID NO:
88), TCTAATACGACTCACTATAGG (SEQ ID NO: 89),
AATTCTAATACGACTCACTATAGG (SEQ ID NO: 90), /5AmMC6/ACTCACTATAGG (SEQ
ID NO: 91), /5AmMC6/AATACGACTCACTATAGG (SEQ ID NO: 92),
/5AmMC6/TCTAATACGACTCACTATAGG (SEQ ID NO: 93), and
/5AmMC6/AATTCTAATACGACTCACTATAGG (SEQ ID NO: 94). In some more
preferred embodiments of oligonucleotide amplification primer pairs
containing an optional heel nucleic acid sequence, the forward
primer of the primer pair is selected from the group consisting
of:
[0172] CAR YTR TTT GTT ACT GTK GTD GA (SEQ ID NO: 3), optionally
having a ACAAT, /5Phos/ACAAT, GGAACAAT, or a /5Phos/GGAACAAT
conjugated to the 5' terminus of the primer; and
[0173] GTD GAT ACY AC HCG YAG TAC HAA (SEQ ID NO: 8), optionally
having a CTGTT or /5Phos/CTGTT conjugated to the 5' terminus of the
primer. In some more preferred embodiments of oligonucleotide
amplification primer pairs containing an optional heel nucleic acid
sequence, the reverse primer of the primer pair is selected from
the group consisting of:
[0174] TGA AAA ATA AAY TGY AAA TCA TAT TCY TCM MCA TG (SEQ ID NO:
9), optionally having a ACTCACTATAGG (SEQ ID NO: 87) or
/5AmMC6/ACTCACTATAGG (SEQ ID NO: 91) conjugated to the 5' terminus
of the primer, TR CAY ARY TGA AAA ATA AAY TG (SEQ ID NO: 11),
optionally having a TCTAATACGACTCACTATAGG (SEQ ID NO: 89) or
/5AmMC6/TCTAATACGACTCACTATAGG (SEQ ID NO: 93) conjugated to the 5'
terminus of the primer; and TR CAY ARY TGA AAA ATA A (SEQ ID NO:
12), optionally having a TCTAATACGACTCACTATAGG (SEQ ID NO: 89) or
/5AmMC6/TCTAATACGACTCACTATAGG (SEQ ID NO: 93) conjugated to the 5'
terminus of the primer.
[0175] The 3' template binding primer region refers to a primer
whose 3' portion binds to a template (e.g., during the first
annealing step to prime polymerization). The above-mentioned primer
design results in the incorporation of the heel sequence in
amplification products after the initial priming event.
Subsequently, the 5' heel sequence acts as a clamp to even the
amplification efficiency across amplicon homologs.
[0176] The extraneous heel sequence may be on either the forward
primer or the reverse primer or both.
[0177] Hence, certain aspects of the present invention contemplate
methods for amplifying a nucleic acid target molecule said methods
comprising subjecting a nucleic acid template of said nucleic acid
target to amplification using forward and reverse primers wherein
at least one primer contains a non-primer binding region 5'
extraneous nucleotide sequence conjugated to a 3' template binding
primer region wherein said extraneous nucleotide sequence is
incorporated into an amplification product after initial
priming.
[0178] As indicated above either the forward or reverse primer may
comprise the extraneous sequence or both may carry the sequence.
When both carry the extraneous sequence, the heel may be the same
or different.
[0179] The present invention is particularly applicable to primers
that are potentially capable of priming a set of nucleic acid
target homologs.
[0180] The present invention further contemplates improved methods
of amplifying a nucleic acid molecule included within a population
of related nucleic acid molecules by amplification with a forward
and reverse primer, comprising: selecting one or both of the
forward or reverse primers such that one or both contain a
non-primer binding region 5' extraneous nucleotide sequence
conjugated to a 3' template binding primer region wherein said
extraneous nucleotide sequence is incorporated into the
amplification production after initial priming.
[0181] Hence, reference to a "nucleic acid molecule" includes a
family of related nucleic acid molecules such as a group of homolog
nucleic acid molecules.
[0182] Kits for reducing amplification bias also form part of the
present invention.
[0183] All scientific citations, patents, patent applications and
manufacturer's technical specifications cited or described in this
document are incorporated herein by reference in their
entirety.
[0184] It is understood that unless otherwise indicated, the
subject invention is not limited to specific reagents, process
steps, or applications or the like, as such may vary. It is also to
be understood that the terminology used herein is for the purpose
of describing particular embodiments only and is not intended to be
limiting.
[0185] Terms and symbols of nucleic acid chemistry, biochemistry,
genetics, and molecular biology used herein follow those of
standard treatises and texts in the field, e.g., Kornberg and
Baker, DNA Replication, Second Edition (W.H. Freeman, New York,
1992); Lehninger, Biochemistry, Second Edition (Worth Publishers,
New York, 1975); Strachan and Read, Human Molecular Genetics,
Second Edition (Wiley-Liss, New York, 1999); Eckstein Ed,
Oligonucleotides and Analogs: A Practical Approach (Oxford
University Press, New York, 1991); Gait Ed, Oligonucleotide
Synthesis: A Practical Approach (IRL Press, Oxford, 1984); and the
like.
[0186] "Amplicon" means the product of a polynucleotide
amplification reaction. That is, it is a population of
polynucleotides, usually but not necessarily double stranded, that
are replicated from one or more starting sequences. The one or more
starting sequences may be one or more copies of the same sequence,
or it may be a mixture of different sequences. Amplicons may be
produced by a variety of amplification reactions whose products are
multiple replicates of one or more target nucleic acids. Generally,
amplification reactions producing amplicons are "template-driven"
in that base pairing of reactants, either nucleotides or
oligonucleotides, have complements in a template polynucleotide
that are required for the creation of reaction products. In one
aspect, template-driven reactions are primer extensions with a
nucleic acid polymerase or oligonucleotide ligations with a nucleic
acid ligase. Such reactions include, but are not limited to PCR
linear polymerase reactions, NASBAs, rolling circle amplifications,
and the like, disclosed in the following references that are
incorporated herein by reference: Mullis et al, U.S. Pat. Nos.
4,683,195; 4,965,188; 4,683,202; 4,800,159 (PCR); Gelfand et al,
U.S. Pat. No. 5,210,015 (real-time PCR with "Taqman" or "Taq"
[registered trade marks] probes); Wittwer et al, U.S. Pat. No.
6,174,670; Kacian et al, U.S. Pat. No. 5,399,491 ("NASBA");
Lizardi, U.S. Pat. No. 5,854,033; Aono et al, Japanese Patent Publ.
No. JP 4-262799 (rolling circle amplification); and the like.
[0187] An amplification reaction may be a "real-time" amplification
where detection chemistry permits a reaction product to be measured
as the amplification reaction progresses.
[0188] The present invention is particularly concerned with
reducing amplification bias across a range of related or homolog
nucleic acid molecules. Examples of homolog nucleic acid molecules
include viral homologs, polymorphisms, related cancer cells,
bacterial homologs, stem cell homologs amongst many others. One
aspect of the present invention is the selection of primers at
potential points of difference between the homologs. The primers
are proposed to carry a non-primer binding region 5' extraneous
nucleotide sequence conjugated to a 3' template binding primer
region which is incorporated into an amplification product after
initial priming.
[0189] The heel or 5' extraneous sequence may be from about 1 to
about 400 bases in length and all combinations and subcombinations
thereof. Preferably the heel is from about 3 to about 100, more
preferably from about 4 to about 80 bases in length, still more
preferably from about 5 to about 40, yet more preferably about 5 to
about 25, with about 10 to about 20 even more preferred.
[0190] In effect, the 5' extraneous sequence optionally has a level
of complementarity to the target sequence, and it does not
contribute substantially to the initial primer binding steps. It is
desirable for the heel to have less than 95% complementarity to the
core primer. Additional examples of the levels of complementarity
can include less than 90%, 85%, 80%, 75%, 70%, 65%, and 60%.
Complementarity is determined using standard algorithms.
[0191] As used herein, the term "amplifying" means performing an
amplification reaction. A "reaction mixture" or "reaction vessel"
means a solution or compartment containing all the necessary
reactants for performing a reaction, which may include, but not be
limited to, buffering agents to maintain pH at a selected level
during a reaction, salts, co-factors, scavengers, and the like.
[0192] "Complementary or substantially complementary" refers to the
hybridization or base pairing or the formation of a duplex between
nucleotides or nucleic acids, such as, for instance, between the
two strands of a dsDNA molecule or between an oligonucleotide
primer and a primer binding site on a single stranded nucleic acid.
Complementary nucleotides are, generally, A and T (or A and U), or
C and G. Two single stranded RNA or DNA molecules are said to be
substantially complementary when the nucleotides of one strand,
optimally aligned and compared and with appropriate nucleotide
insertions or deletions, pair with at least about 80% of the
nucleotides of the other strand, usually at least about 90% to 95%,
and more preferably from about 98 to 100%. Alternatively,
substantial complementarity exists when, for example, a DNA strand
hybridizes under selective hybridization conditions to its
complement. Typically, selective hybridization occurs when there is
at least about 65% complementary over a stretch of at least 14 to
25 nucleotides, preferably at least about 75%, more preferably at
least about 90% complementary. See, Kanehisa Nucleic Acids Res.
12:203, 1984, incorporated herein by reference in its entirety.
[0193] "Duplex" means at least two oligonucleotides and/or
polynucleotides that are fully or partially complementary undergo
Watson-Crick type base pairing among all or most of their
nucleotides so that a stable complex is formed. The terms
"annealing" and "hybridization" are used interchangeably to mean
the formation of a stable duplex. "Perfectly matched" in reference
to a duplex means that the poly- or oligonucleotide strands making
up the duplex form a double stranded structure with one another
such that every nucleotide in each strand undergoes Watson-Crick
base pairing with a nucleotide in the other strand.
[0194] "Genetic locus," or "locus" in reference to a genome or
target polynucleotide, means a contiguous subregion or segment of
the genome or target polynucleotide. As used herein, genetic locus,
or locus, may refer to the position of a gene or portion of a gene
in a genome, or it may refer to any contiguous portion of genomic
sequence whether or not it is within, or associated with, a gene.
Preferably, a genetic locus refers to any portion of genomic
sequence from a few tens of nucleotides, e.g., 10-30, or 10-100, in
length, to a few hundred nucleotides, e.g., 100-1000 or 100-500 in
length, to a few thousands of nucleotide in length, e.g.,
1000-10,000 or 1000-3000 in length. In some contexts, genetic loci
may refer to the location of a nucleotide within a genome.
[0195] "Kit" refers to any delivery system for delivering materials
or reagents for carrying out a method of the instant invention. In
the context of reaction assays, such delivery systems include
systems that allow for the storage, transport, or delivery of
reaction reagents (e.g., probes, enzymes, etc., in the appropriate
containers) and/or supporting materials (e.g., buffers, written
instructions for performing the assay etc.) from one location to
another. For example, kits include one or more enclosures (e.g.,
boxes) containing the relevant reaction reagents and/or supporting
materials. Such contents may be delivered to the intended recipient
together or separately. For example, a first container may contain
an enzyme for use in an assay, while a second container contains
probes. The kits may also contain compartments adapted to contain
the reagents. In one example, a compartment comprises a solid
matrix having oligonucleotides or primers or polynucleotides
immobilized thereon which participate in the amplification
reaction. An example of a solid matrix is a microarray. A kit,
therefore, may be part of an overall amplification system having a
reagent component, a nucleic acid component, a hardware component
and an instructional component.
[0196] "Microarray" refers to a solid phase support having a planar
surface, which carries an array of nucleic acids, each member of
the array comprising identical copies of an oligonucleotide or
polynucleotide immobilized to a spatially defined region or site,
which does not overlap with those of other members of the array;
that is, the regions or sites are spatially discrete. Spatially
defined hybridization sites may additionally be "addressable" in
that its location and the identity of its immobilized
oligonucleotide are known or predetermined, for example, prior to
its use. Typically, the oligonucleotides or polynucleotides are
single stranded and are covalently attached to the solid phase
support, usually by a 5'-end or a 3'-end. The density of
non-overlapping regions containing nucleic acids in a microarray is
typically greater than 100 per cm.sup.2, and more preferably,
greater than 1000 per cm.sup.2. Microarray technology is disclosed
in the following references that are incorporated by reference in
its entirety: Schena, Ed, Microarrays: A Practical Approach (IRL
Press, Oxford, 2000); Southern, Current Opin. Chem. Biol.,
2:404-410, 1998.
[0197] A "random microarray" refers to a microarray whose spatially
discrete regions of oligonucleotides or polynucleotides are not
spatially addressed. That is, the identity of the attached
oligonucleotides or polynucleotides is not discernable, at least
initially, from its location. In one aspect, random microarrays are
planar arrays of microbeads wherein each microbead has attached a
single kind of hybridization tag complement, such as from a
minimally cross-hybridizing set of oligonucleotides. Likewise,
after formation, microbeads, or oligonucleotides thereof, in a
random array may be identified in a variety of ways, including by
optical labels, e.g., fluorescent dye ratios or quantum dots,
shape, sequence analysis, or the like.
[0198] "Nucleoside" as used herein includes the natural
nucleosides, including 2'-deoxy and T-hydroxyl forms, e.g., as
described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman,
San Francisco, 1992).
[0199] "Polymerase chain reaction," or "PCR," means a reaction for
the in vitro amplification of specific DNA sequences by the
simultaneous primer extension of complementary strands of DNA. In
other words, PCR is a reaction for making multiple copies or
replicates of a target nucleic acid flanked by primer binding
sites, such reaction comprising one or more repetitions of the
following steps: (i) denaturing the target nucleic acid, (ii)
annealing primers to the primer binding sites, and (iii) extending
the primers by a nucleic acid polymerase in the presence of
nucleoside triphosphates. Usually, the reaction is cycled through
different temperatures optimized for each step in a thermal cycler
instrument. Particular temperatures, durations at each step, and
rates of change between steps depend on many factors well-known to
those of ordinary skill in the art, e.g., exemplified by the
references: McPherson et al, (Eds), PCR: A Practical Approach and
PCR2: A Practical Approach (IRL Press, Oxford, 1991 and 1995,
respectively). For example, in a conventional PCR using Taq DNA
polymerase, a double stranded target nucleic acid may be denatured
at a temperature >90.degree. C., primers annealed at a
temperature in the range 35-90.degree. C. The term "PCR"
encompasses derivative forms of the reaction, including but not
limited to, RT-PCR, real-time PCR, nested PCR, quantitative PCR,
multiplexed PCR, enhanced solid phase PCR, and the like. For
further detail of enhanced solid phase PCR, see, for example, Park,
et al., Analytical Biochemistry, 375 (2008), pp. 391-393, the
entirety of which is incorporated herein by reference in its
entirety. The use of enhanced solid phase PCR is preferred in
certain embodiments of the present invention for the generation
and/or amplification of nucleic acid molecules related to, for
example HPV strains. Still more preferred is the use of one or more
forward/reverse primer pairs noted herein in enhanced solid phase
PCR amplification of nucleic acid molecules related to HPV
strains.
[0200] Using the ESP-PCR format, 5-prime phosphates are optional
since single stranded amplicon is not required as a final PCR
product. The 5-prime amine functional groups are also optional in
this format and may be used as a preferred means of labelling with
a fluorophore for signal generation. However, many alternative
means of signal generation may also be employed where there is no
requirement for any functional group or an alternative functional
group. For example, PCR primers may be non-fluor labelled, and
separate `signal oligonucleotides`, which are conjugated with a
signal, may be employed. In another example, using ESP-PCR format,
all `aqueous` PCR primers may be used without functional groups and
the signal could alternatively be introduced by means of labelled
nucleotide analogue incorporation. In other embodiments using
ESP-PCR format, all `aqueous` PCR primers may be used without
functional groups, and the signal could be introduced by means of
labelled solid support primer such that signal increases in the
context of double stranded product.
[0201] Alternative means for the generation of single stranded
amplicon include conversion of double stranded DNA to single
stranded DNA by separating the strands or by removing one strand of
the duplex. Strands of the duplex can be separated by thermal or
chemical means of disrupting interstrand bonds. Removal of one
strand permits recovery of the desired strand and elimination of
its complement e.g., Nikiforov et al. (U.S. Pat. No. 5,518,900),
who described modifying one of two primers used for amplification
by incorporation of phosphorothiate nucleotide derivatives in the
5' end of the modified primer, rendering it resistant to
exonuclease digestion. After amplifying target sequences using the
polymerase chain reaction (PCR), the dsDNA is subjected to
exonuclease digestion. The unprotected strand is preferentially
digested by a 5' to 3' exonuclease, leaving a single-stranded
product consisting of the other strand. Similar strategies have
used exonuclease-resistant branched primers (Shchepinov et al.,
Nuc. Acids. Res. 25:4447-4454 1997) or 5' phosphate-bearing
substrate preference of Lambda exonuclease (Higuchi et al., Nucl.
Acids Res. 25:5685, 1989)
[0202] Asymmetric PCR (Gyllensten and Erlich, Proc. Natl. Acad.
Sci. USA 85:7652-7656 1998; U.S. Pat. No. 5,066,584) generates
ssDNA during thermocycling by employing an imbalanced primer pair
concentration such that one primer is at a limiting concentration.
This favours ssDNA product primed by the primer in excess.
[0203] Competitor primer asymmetric PCR (Gillespie, 1997; U.S.
patent application Ser. No. 08/628,417) employs the separate
addition of competitor primer following PCR thermocycling and prior
to further thermocycling to generate ssDNA. Kaltenboeck et al.,
Biotechniques 12:164-171, 1992 described a method of producing
ssDNA by initially performing a PCR to generate dsDNA, followed by
a separate reaction using the product of the first PCR as a
template for a second linear amplification employing one primer.
See also U.S. Pat. No. 6,887,664 for examples of Asynchronous
PCR.
[0204] Reaction volumes range from a few hundred nanoliters, e.g.,
200 mL, to a few hundred .mu.L, e.g., 200 pt. "Reverse
transcription PCR," or "RT-PCR," means a PCR that is preceded by a
reverse transcription reaction that converts a target RNA to a
complementary single stranded DNA, which is then amplified, e.g.,
Tecott et al, U.S. Pat. No. 5,168,038, which patent is incorporated
herein by reference in its entirety. "Real-time PCR" means a PCR
for which the amount of reaction product, i.e., amplicon, is
monitored as the reaction proceeds. There are many forms of
real-time PCR that differ mainly in the detection chemistries used
for monitoring the reaction product, e.g., Gelfand et al, U.S. Pat.
No. 5,210,015 ("taqman"); Wittwer et al, U.S. Pat. Nos. 6,174,670
and 6,569,627 (intercalating dyes); Tyagi et al, U.S. Pat. No.
5,925,517 (molecular beacons); which patents are incorporated
herein by reference in its entirety. Detection chemistries for
real-time PCR are reviewed in Mackay et al, Nucleic Acids Research,
30:1292-1305, 2002, which is also incorporated herein by reference
in its entirety. "Nested PCR" means a two-stage PCR wherein the
amplicon of a first PCR becomes the sample for a second PCR using a
new set of primers, at least one of which binds to an interior
location of the first amplicon.
[0205] It is proposed that the initial priming events be made with
forward and reverse primers where one or both carry a non-primer
binding region 5' extraneous nucleotide sequence conjugated to a 3'
template binding primer region wherein the extraneous nucleotide
sequence is incorporated into an amplification product after
initial priming.
[0206] The use of non-primer binding region 5' heel sequence
conjugated to a 3' template binding primer region as the primer
design results in the incorporation of the heel sequence in
amplification products after the initial primer binding event.
Subsequently, the 5' heel sequence acts as a clamp to even the
amplification efficiency across homologs. As such, amplification
bias is restricted to initial primer binding events. The "heel
clamp" can be placed on either or both forward and reverse primers
depending on requirement. There is great freedom of design
regarding what sequence the "heel clamp" sequence was comprised to
suit the particular application. The 3' template binding primer
sequence could take the form of degenerate sequence, consensus
sequence, or a hybrid of consensus and degenerate sequences. A pool
of exact matching sequences of interest could also be employed. In
all these cases the 5' "heel clamp" principle can be employed.
[0207] "Polynucleotide" and "oligonucleotide" are used
interchangeably and each mean a linear polymer of nucleotide
monomers. Monomers making up polynucleotides and oligonucleotides
are capable of specifically binding to a natural polynucleotide by
way of a regular pattern of monomer-to-monomer interactions, such
as Watson-Crick type of base pairing, base stacking, Hoogsteen or
reverse Hoogsteen types of base pairing, or the like.
[0208] Whenever a polynucleotide or oligonucleotide is represented
by a sequence of letters (upper or lower case), such as "ATGCCTG,"
it will be understood that the nucleotides are in 5'->3' order
from left to right and that "A" denotes deoxyadenosine, "C" denotes
deoxycytidine, "G" denotes deoxyguanosine, and "T" denotes
thymidine, "I" denotes deoxyinosine, "U" denotes uridine, unless
otherwise indicated or obvious from context.
[0209] "Primer" means an oligonucleotide, either natural or
synthetic that is capable, upon forming a duplex with a
polynucleotide template, of acting as a point of initiation of
nucleic acid synthesis and being extended from its 3' end along the
template so that an extended duplex is formed.
[0210] Extension of a primer is usually carried out with a nucleic
acid polymerase, such as a DNA or RNA polymerase. The sequence of
nucleotides added in the extension process is determined by the
sequence of the template polynucleotide. Usually primers are
extended by a DNA polymerase. Primers usually have a length in the
range of from 14 to 40 nucleotides, or in the range of from 18 to
36 nucleotides. Primers are employed in a variety of nucleic
amplification reactions, for example, linear amplification
reactions using a single primer, or PCRs, employing two or more
primers. Guidance for selecting the lengths and sequences of
primers for particular applications is well known to those of
ordinary skill in the art, as evidenced by the following references
that are incorporated by reference in its entirety: Dieffenbach
(Ed), PCR Primer: A Laboratory Manual, 2.sup.nd Edition (Cold
Spring Harbor Press, New York, 2003).
[0211] "Sample" means a quantity of material from a biological,
environmental, medical, or patient source in which detection or
measurement of target nucleic acids is sought. On the one hand it
is meant to include a specimen or culture (e.g., microbiological
cultures). On the other hand, it is meant to include both
biological and environmental samples. A sample may include a
specimen of synthetic origin. Biological samples may be animal,
including human, fluid, solid (e.g., stool) or tissue, as well as
liquid and solid food and feed products and ingredients such as
dairy items, vegetables, meat and meat by-products, and waste.
Biological samples may include materials taken from a patient
including, but not limited to cultures, blood, saliva, cerebral
spinal fluid, pleural fluid, milk, lymph, sputum, semen, needle
aspirates, and the like. Biological samples may be obtained from
all of the various families of domestic animals, as well as feral
or wild animals, including, but not limited to, such animals as
ungulates, bear, fish, rodents, etc. Environmental samples include
environmental material such as surface matter, soil, water and
industrial samples, as well as samples obtained from food and dairy
processing instruments, apparatus, equipment, utensils, disposable
and non-disposable items. These examples are not to be construed as
limiting the sample types applicable to the present invention.
[0212] Hence, some aspects of the present invention provide methods
for amplifying a nucleic acid target molecule, comprising:
subjecting a single stranded template of said nucleic acid target
to amplification using forward and reverse primers wherein at least
one primer contains a non-primer binding region 5' extraneous
nucleotide sequence conjugated to a 3' template binding primer
region wherein said extraneous nucleotide sequence is incorporated
into an amplification product after initial priming.
[0213] Other aspects of the present invention contemplate improved
methods of amplifying a nucleic acid molecule including within a
population of related nucleic acid molecules by amplification with
a forward and reverse primer, comprising: selecting one or both of
the forward or reverse primers such that one or both contain a
non-primer binding region 5' extraneous nucleotide sequence
conjugated to a 3' template binding primer region wherein said
extraneous nucleotide sequence is incorporated into the
amplification production after initial priming.
[0214] Examples of heel sequences include:
TABLE-US-00008 T7a promoter sequence 25-mer: (SEQ ID NO: 95) AAT
TCT AAT ACG ACT CAC TAT AGG G; M13/pUC Sequencing Primer (-40) (SEQ
ID NO: 96) GTT TTC CCA GTC ACG AC; M13/pUC sequencing primer (-20),
17-mer (SEQ ID NO: 97) GTA AAA CGA CGG CCA GT; M13/pUC reverse
sequencing primer (-26), 17-mer (SEQ ID NO: 98) CAG GAA ACA GCT ATG
AC; M13/pUC sequencing primer (-40), 17-mer (SEQ ID NO: 96) GTT TTC
CCA GTC ACG AC; M13/pUC sequencing primer (-46), 22-mer (SEQ ID NO:
99) GCC AGG GTT TTC CCA GTC ACG A; M13/pUC reverse sequencing
primer (-46), 24-mer (SEQ ID NO: 100) GAG CGG ATA ACA ATT TCA CAC
AGG; SP6 promoter sequencing primer, 18-mer (SEQ ID NO: 101) ATT
TAG GTG ACA CTA TAG; SP6 promoter sequencing primer, 24-mer (SEQ ID
NO: 102) CAT ACG ATT TAG GTG ACA CTA TAG; T7 promoter sequencing
primer, 20-mer (SEQ ID NO: 103) TAA TAC GAC TCA CTA TAG GG; T3
promoter sequencing primer, 17-mer (SEQ ID NO: 104) ATT AAC CCT CAC
TAA AG; and, T3 promoter sequencing primer, 24-mer (SEQ ID NO: 105)
GCG CGA AAT TAA CCC TCA CTA AAG.
[0215] Amplification from primer sites such as those described
above effectively allows the use of a "universal" primer set, which
bind at C and C' to amplify X from a range of strains of the
analyte. Furthermore, it should be noted that the amplicon
amplified using the universal primers may comprise both conserved
and variable regions.
[0216] In some embodiments, primers are used which amplify HPV
sequences. More preferably these primers are GPS+ is 5' TTT GTT ACT
GTG GTA GAT ACT AC 3'(SEQ ID NO: 13) and GP6+ is 5' GAA AAA TAA ACT
GTA AAT CAT ATT C 3'(SEQ ID NO: 14). These primers generate an
amplicon from HPV which comprises both a conserved region (defined
as Y in FIG. 2), and a region which is variable among different
strains of HPV (defined as X in FIG. 2).
[0217] In other embodiments, these primers are GP5d2+ is 5' TTT KTT
ACH GTK GTD GAT ACH AC 3' (SEQ ID NO: 21) and T7aGP6d+ is 5' AAT
TCT AAT ACG ACT CAC TAT AGG GGA AAH ATA AAY TGY AAD TCA TAY TC 3'
(SEQ ID NO: 22).
[0218] In another embodiment, these primers are GP5d3+ is 5' 5Phos
TTT GTT ACH GTD GTD GAY ACH AC 3'(SEQ ID NO: 27) and T7aGP6d+* is
5' /5AmMC6/AAT TCT AAT ACG ACT CAC TAT AGG GGA AAH ATA AAY TGY ARD
TCA WAY TC 3' (SEQ ID NO: 24).
[0219] In other embodiments, the forward primers of a primer pair
are selected from the group consisting of:
[0220] TR TTT GTT ACT GTK GTD GAT ACY A (SEQ ID NO: 1), optionally
having a caatcagc or /5Phos/caatcagc conjugated to the 5' terminus
of the primer;
[0221] CAR YTR TTT GTT ACT GTK GTD GAT A (SEQ ID NO: 2), optionally
having a acaat or /5Phos/acaat conjugated to the 5' terminus of the
primer;
[0222] CAR YTR TTT GTT ACT GTK GTD GA (SEQ ID NO: 3), optionally
having a acaat or /5Phos/acaat conjugated to the 5' terminus of the
primer;
[0223] AAY CAR YTR TTT GTT ACT GTK GT (SEQ ID NO: 4), optionally
having a ggaac or /5Phos/ggaac conjugated to the 5' terminus of the
primer;
[0224] TTT GTT ACT GTK GTD GAT ACY AC HCG (SEQ ID NO: 5),
optionally having a cagctt or /5Phos/cagctt conjugated to the 5'
terminus of the primer;
[0225] TTT GTT ACT GTK GTD GAT ACY AC HCG YAG (SEQ ID NO: 6),
optionally having a cagctt or /5Phos/cagctt conjugated to the 5'
terminus of the primer;
[0226] GTK GTD GAT ACY AC HCG YAG TAC (SEQ ID NO: 7), optionally
having a attac or /5Phos/attacc conjugated to the 5' terminus of
the primer; and
[0227] GTD GAT ACY AC HCG YAG TAC HAA (SEQ ID NO: 8), optionally
having a ctgtt or /5Phos/ctgtt conjugated to the 5' terminus of the
primer; and the reverse primers of a primer pair are selected from
the group consisting of:
[0228] TGA AAA ATA AAY TGY AAA TCA TAT TCY TCM MCA TG (SEQ ID NO:
9), optionally having a actcactatagg (SEQ ID NO: 87) or
/5AmMC6/actcactatagg (SEQ ID NO: 91) conjugated to the 5' terminus
of the primer;
[0229] CAY ARY TGA AAA ATA AAY TGY AAA TC (SEQ ID NO: 10),
optionally having a aatacgactcactatagg (SEQ ID NO: 88) or
/5AmMC6/aatacgactcactatagg (SEQ ID NO: 92) conjugated to the 5'
terminus of the primer;
[0230] TR CAY ARY TGA AAA ATA AAY TG (SEQ ID NO: 11), optionally
having a tctaatacgactcactatagg (SEQ ID NO: 89) or
/5AmMC6/tctaatacgactcactatagg (SEQ ID NO: 93) conjugated to the 5'
terminus of the primer; and
[0231] TR CAY ARY TGA AAA ATA AA (SEQ ID NO: 12), optionally having
a aattctaatacgactcactatagg (SEQ ID NO: 90) or
/5AmMC6/aattctaatacgactcactatagg (SEQ ID NO: 94) conjugated to the
5' terminus of the primer. Alternatively, the forward and reverse
primers are selected from a group of primers similar to those
described hereinabove, but which may differ from the forward or
reverse primers described hereinabove by from 0 to about 5
nucleotide substitutions, preferably 0 to about 2 substitutions, at
sites where nucleotide substitutions occur between different HPV
strains, but with the exclusion of substitutions of the last two
nucleotides at the 3' end. The invention also contemplates similar
substitutions to optional heel sequences as those for forward or
reverse primers described hereinabove, said optional heels
conjugated to the 5'' terminus of any of the above disclosed
forward or reverse primers. In certain preferred embodiments, the
forward primer is selected from CAR YTR TTT GTT ACT GTK GTD GA (SEQ
ID NO: 3), optionally having a acaat or /5Phos/acaat conjugated to
the 5' terminus of the primer and GTD GAT ACY AC HCG YAG TAC HAA
(SEQ ID NO: 8), optionally having a ctgtt or/5Phos/ctgtt conjugated
to the 5' terminus of the primer. In certain other preferred
embodiments, the reverse primer is selected from TGA AAA ATA AAY
TGY AAA TCA TAT TCY TCM MCA TG (SEQ ID NO: 9), optionally having a
actcactatagg (SEQ ID NO: 87) or /5AmMC6/actcactatagg (SEQ ID NO:
91) conjugated to the 5' terminus of the primer and TR CAY ARY TGA
AAA ATA AAY TG (SEQ ID NO: 11), optionally having a
tctaatacgactcactatagg (SEQ ID NO: 89) or
/5AmMC6/tctaatacgactcactatagg (SEQ ID NO: 93) conjugated to the 5'
terminus of the primer.
[0232] The above descriptions show examples of primer pairs useful
in the present invention. Additional primer pairs can be formed by
pairing different forward (e.g., GPS+, GP5d2+, etc.) and reverse
primers (e.g., GP6+, T7aGP6d+) with one another.
[0233] Certain embodiments of the invention are directed to
fragments of any of the herein disclosed primers including all
combinations and subcombinations of said primer fragments, to a
lower limit of about 20-mer 3-prime core fragments of any of the
disclosed primers. As used herein, a "fragment" refers to a
truncated primer or probe nucleic acid oligomeric sequence formed
by deletion of one or more nucleotides from the original
primer.
[0234] The present invention also contemplates the amplification of
control sequences. In one embodiment, the control sequence may
include a region of the genome of the subject from which a
biological sample is derived. However, the present invention is not
in any way limited to these particular control sequences and other
control sequences which would be evident to one of skill in the art
are also contemplated. Furthermore, the methods of the present
invention may also be performed without the amplification of a
control sequence.
[0235] In some embodiments, the control sequence is amplified from
the genome of a human subject using the primers MLC1_F, which
comprises the nucleotide sequence 5' TAC ACA CAG GTG TAC ACA GA 3'
(SEQ ID NO: 106) and MLC1_R which comprises the sequence 5' ACC AAG
TAC TCT ACG TGT TG 3' (SEQ ID NO: 107).
[0236] In other embodiments, the control sequence is amplified from
the genome of a human subject using the primers mlc1.sub.--95f,
which comprises the nucleotide sequence 5' GGC ACC CAG ACA TAC AC
3' (SEQ ID NO: 108) and T7 amlc1.sub.--275r (HeelMLCR), which
comprises the sequence 5' AAT TCT AAT ACG ACT CAC TAT AGG GGA AAH
ATA AAY TGY AAD TCA TAY TC 3' (SEQ ID NO: 30).
[0237] Isolated DNA may be amplified using any DNA amplification
protocol. A range of exemplary methods for the amplification of DNA
which in no way limit the invention are presented in "DNA
Amplification: Current Technologies and Applications" (Demidov and
Broude Eds., Horizon Bioscience, 2004).
[0238] Isolated RNA may be amplified using any RNA methods known in
the art and number of RNA amplification technologies have been
developed. Two major categories of these are: (i) those that
utilise thermal cycling such as RT-PCR and (ii) isothermal assays
such as nucleic acid sequence-based amplification (NASBA) (Compton,
Nature 350:91-92, 1991; Kievits et al., J. Virol. Methods
35:273-286, 1991) and transcription-mediated amplification (TMA)
(Hill, J. Clin. Ligand Assay 19:43-51, 1996). Isothermal assays may
be sub-divided, based on whether: (i) they copy and amplify the
target sequence, such as TMA, NASBA and self-sustained sequence
replication (3SR) (Guatelli et al., Proc. Natl. Acad. Sci. USA
87:1874-1878, 1990; Chadwick et al., J. Virol. Methods 70:59-70,
1998; for review see Chan and Fox, Rev. Med. Microbiol. 10:185-196,
1999), or (ii) they generate a target-dependent signal which can be
further amplified, e.g., invader assays (Lyamichev et al., Nat.
Biotechnol. 17:292-296, 1999; Ryan et al., Mol. Diagn. 4:135-144,
1999). There are various other amplification technologies that do
not fit readily into these categories, such as Q beta replicase
(Lizardi et al., Biotechnology 6:1197-1202, 1988) and branched DNA
(Todd et al., J. AIDS Hum. Retrovirol. 10:S35-S44, 1995; Pawlotsky
et al., J. Virol. Methods 79:227-235, 1999). However, it should be
understood that the present invention contemplates any method of
RNA amplification that would be evident to one of skill in the art.
Furthermore, it should be understood that the present invention
also contemplates the use of reverse transcriptase or a functional
equivalent thereof to convert RNA to DNA which may then be
subsequently amplified.
[0239] In accordance with the present invention, the amplicons
recited at steps (iii) and/or (iv) of the methods described supra
are labelled. The amplicons of the present invention may be
labelled using any convenient means. Exemplary methods include both
pre- and post-synthesis methods. Pre-synthesis labelling methods
include labelling of a PCR primer that is subsequently used for
amplification of, and thereby incorporated into, an amplicon via
PCR. In this method, the label is typically attached to the 5' end
of a primer suitable for the amplification of the amplicon,
although labelling at other positions within the primer, such as 3'
labelling or non-terminal labelling, is also contemplated.
[0240] A chemical linker may also be used between the label and the
polynucleotide which is labelled. Appropriate linker sequences will
be readily ascertained by those of skill in the art, and are likely
to include linkers such as C.sub.6, C.sub.7 and C.sub.12 amino
modifiers and linkers comprising thiol groups. As will be readily
ascertained, a primer may comprise the linker and label, or the
linker alone, to which the label may be attached at a later
stage.
[0241] Post-amplification labelling methods include nick-labelling
systems wherein a labelled polynucleotide is synthesised from the
amplicon using Klenow polymerase, or a functional equivalent
thereof, from random primers. Labelled nucleotides, or nucleotides
comprising a linker group, may be incorporated into the Klenow
polymerase synthesised polynucleotide during synthesis.
[0242] In any event, other labelling methods should be readily
evident to one of skill in the art and it should be understood that
the present invention is in no way defined or limited by the choice
of labelling method.
[0243] Preferably, the label used is a "fluorescent marker" or
"fluorophore". Many different fluorescent markers will be familiar
to those of skill in the art, and the choice of fluorescent marker
in no way limits the invention. In other preferred embodiments of
the present invention the fluorescent markers of the present
invention comprise any fluorescent marker that can be attached to a
polynucleotide and which is excitable using a light source selected
from the group below: [0244] (i) Argon ion lasers: comprise a blue,
488 nm line, which is suitable for the excitation of many dyes and
fluorochromes that fluoresce in the green to red region. Tunable
argon lasers are also available that emit at a range of wavelengths
(458 nm, 488 nm, 496 nm, 515 nm and others). [0245] (ii) Diode
lasers: have an emission wavelength of 635 nm. Other diode lasers
which are now available operate at 532 nm. Interestingly, this
wavelength excites propidium iodide (PI) optimally. PI staining is
widely used for DNA analysis, live/dead counting and ploidy
determination. Blue diode lasers emitting light around 476 nm are
also available [0246] (iii) HeNe gas lasers: operate with the red
633 nm line. [0247] (iv) HeCd lasers: operate at 325 nm. [0248] (v)
100 W mercury arc lamp: the most efficient light source for
excitation of UV dyes like Hoechst and DAPI.
[0249] In more preferred embodiments of the present invention the
fluorescent markers are selected from: hydroxycoumarin,
aminocoumarin, methoxycoumarin, cascade blue, Lucifer yellow, NBD,
Phyccerythrin (PE), PerCP, allophycocyanin, Hoechst 33342, DAP1,
SYTOX Blue, Hoechst 33258, chromomycin A3, mithramycin, YOYO-1,
SYTOX green, SYTOX orange, 7-AAD, acridine orange, TOTO-1,
To-PRO-1, thiazole orange, TOTO-3, TO-PRO-3, LDS 751, Alexa Fluor
dyes including Alexa Fluoro-350, -430, -488, -532, -546, -555,
-556, -594, -633, -647, -660, -680, -700 and -750; BoDipy dyes,
including BoDipy 630/650 and BoDipy 650/665; CY dyes, particulary
Cy2, Cy3, Cy3.5, Cy5, Cy 5.5 and Cy7; 6-FAM (Fluorescein); PE-Cy5,
PE-Cy7, Fluorescein dT; Hexachlorofluorescein (Hex);
6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE); Oregon
green dyes, including 488-X and 514; Rhodamine dyes, including
X-Rhodamine, Lissamine Rhodamine B, Rhodamine Green, Rhodamine Red
and ROX; TRITC, Tetramethylrhodamine (TMR);
Carboxytetramethylrhodamine (TAMRA); Tetrachlorofluorescein (TET);
Red 6B, Fluor X, BODIPY-FL, SYBR Green I dye, and Texas Red. In
particularly preferred embodiments of the present invention, the
marker is Cy5 which is particularly convenient for practice of the
present invention.
[0250] However, in alternate embodiments of the invention,
radioactive or non-radioactive labels may be used to label the
amplicon. Convenient radioactive labels include .sup.32P and
.sup.3H. These labels may be incorporated into the amplicon and/or
primer using any convenient means. A range of non-radioactive
labelling methods may also be used. Exemplary non-radioactive
labelling methods which in no way limit the present invention are
presented in Speel (Histochem. Cell Biol. 112:89-113, 1999).
[0251] The term "reactant" as used herein should be understood to
comprise a polynucleotide immobilized to a bead. More particularly,
each reactant comprises a polynucleotide comprising a sequence
which is complementary to an amplicon generated according to the
methods described herein, which is bound or otherwise associated
with a physiochemically distinguishable bead. A reactant may also
comprise a sequence which is complementary to a control sequence as
hereinbefore defined, i.e., a sequence amplified from the genome of
a multicellular organism (Z) or the amplicon of a nucleotide
sequence which is conserved among strains of the analyte (Y).
[0252] Accordingly, a beadset of reactants may comprise:
[B.sub.1-cX.sub.1,B.sub.2-cX.sub.2,B.sub.3-cX.sub.3 . . .
B.sub.y-cX.sub.n,B.sub.y-cY,B.sub.Z-cZ]
wherein: B.sub.1 . . . B.sub.n, B.sub.y, B.sub.Z are each
physiochemically distinguishable beads; cX.sub.n is a
polynucleotide immobilized to a bead wherein said polynucleotide
comprises a nucleotide sequence which is complementary to a
particular nucleic acid sequence which is specific to an analyte or
a particular strain of a subject analyte and wherein n is the
number of analytes or particular strains of a subject analyte to be
detected using the beadset; cY is an optional member of the beadset
and is a polynucleotide immobilized to a bead wherein said
polynucleotide comprises a nucleotide sequence which is
complementary to a sequence which is conserved among the analytes
or strains of a subject analyte; cZ is an optional member of the
beadset and is a polynucleotide immobilized to a bead wherein said
polynucleotide comprises a nucleotide sequence which is
complementary to a control sequence which is amplified from a
multicellular subject.
[0253] Preferably, the subject analyte is HPV and the control DNA
sequence is a human genomic DNA sequence.
[0254] By "complementary", it is to be understood that the
immobilized polynucleotide of the reactant should hybridize to an
amplicon generated according to the methods described herein under
low stringency conditions. Preferably the immobilized
polynucleotide should bind to the sample and standard under medium
stringency conditions, and most preferable the immobilized
polynucleotide should bind to the sample and standard under high
stringency conditions.
[0255] Reference herein to low stringency includes and encompasses
from at least about 0 to at least about 15% v/v formamide
(including 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10% 11%, 12%, 13%
and 14% v/v formamide) and from at least about 1 M to at least
about 2 M salt for hybridization, and at least about 1 M to at
least about 2 M salt for washing conditions. Generally, low
stringency is at from about 25-30.degree. C. to about 52.degree.
C., such as 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 and 52.degree.
C. The temperature may be altered and higher temperatures used to
replace formamide and/or to give alternative stringency conditions.
Alternative stringency conditions may be applied where necessary,
such as medium stringency, which includes and encompasses from at
least about 16% v/v to at least about 30% v/v formamide, including
16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 24%, 26%, 27%, 28%,
29% and 30% v/v formamide, and from at least about 0.5 M to at
least about 0.9 M salt for hybridization, and at least about 0.5 M
to at least about 0.9 M salt for washing conditions, or high
stringency, which includes and encompasses from at least about 31%
v/v to at least about 50% v/v formamide and from at least about
0.01 M to at least about 0.15 M salt for hybridization, and at
least about 0.01 M to at least about 0.15 M salt for washing
conditions. In general, washing is carried out T.sub.m=69.3+0.41
(G+C) % (Marmur and Doty, J. Mol. Biol. 5:109, 1962). However, the
T.sub.m of a duplex DNA decreases by 1.degree. C. with every
increase of 1% in the number of mismatch base pairs (Bonner and
Laskey, Eur. J. Biochem. 46:83, 1974). Formamide is optional in
these hybridization conditions. Accordingly, particularly preferred
levels of stringency are defined as follows: low stringency is
6.times.SSC buffer, 0.1% w/v SDS at 25-42.degree. C.; a moderate
stringency is 2.times.SSC buffer, 0.1% w/v SDS at a temperature in
the range 20.degree. C. to less than 65.degree. C.; high stringency
is 0.1.times.SSC buffer, 0.1% w/v SDS at a temperature of at least
65.degree. C.
[0256] The beads, B.sub.1 . . . B.sub.n, B.sub.y, B.sub.Z, of the
reactant beadsets are each physiochemically distinguishable beads.
The term "physiochemically distinguishable" refers to any physical
or chemical characteristic which allows one bead, e.g., B.sub.1 to
be differentiated from another bead e.g., B.sub.2. Accordingly, the
physiochemically distinguishable beads allow differentiation of
particular reactants.
[0257] In certain preferred embodiments the bead comprises a
"microparticle". As will be evident to those of skill in the art,
almost any material, homogeneous or otherwise may be used for the
microparticle. The microparticles contemplated herein may also
comprise more than one substance, and as such may comprise shells,
alloys or mixtures of organic and/or inorganic substances.
Particularly useful materials which may be used in accordance with
the present invention and which represent preferred embodiments of
the present invention include materials selected from the list
consisting of: silica (for example: quartz or glass), latex,
titania, tin dioxide, yttria, alumina, and other binary metal
oxides (such as ZnO), perovskites and other piezoelectric metal
oxides (such as BaTiO.sub.3), ZnS, sucrose, agarose and other
polymeric beads. In a particularly preferred embodiment, the
microparticle comprises silica.
[0258] In some preferred embodiments, the term "physiochemically
distinguishable" refers to a measurable difference in any of bead
size, the presence or absence of a particular optically detectable
label and/or the intensity of an optically detectable label.
[0259] Beads contemplated by the present invention may be produced
in any convenient regular or irregular 3-dimensional shape.
However, it is generally practical to synthesize small spheres or
spheroidal particles. Such spheres or spheroidal particles are also
referred to herein as "beads". Accordingly, in preferred
embodiments of the present invention, the "microparticles" of the
present invention are substantially spherical or spheroidal or
comprise a "microsphere".
[0260] Although the beads of the present invention may be referred
to as "microspheres" the actual size of the particles depends on a
variety of factors and the particles may or may not actually
comprise measurements in the micrometer range. In some preferred
embodiments, the bead comprises a diameter (or equivalent
measurement in a non-spheroidal particle) of about 300 nm to about
30 .mu.m, including 300 nm, 350 nm, 400 nm, 450 nm, 500 nm, 550 nm,
600 nm, 650 nm, 700 nm, 750 nm, 800 nm, 850 nm, 900 nm, 950 nm, 1.0
.mu.m, 1.1 .mu.m, 1.2 .mu.m, 1.3 .mu.m, 1.4 .mu.m, 1.5 .mu.m, 1.6
.mu.m, 1.7 .mu.m, 1.8 .mu.m, 1.9 .mu.m, 2.0 .mu.m, 2.1 .mu.m, 2.2
.mu.m, 2.3 .mu.m, 2.4 .mu.m, 2.5 .mu.m, 2.6 .mu.m, 2.7 .mu.m, 2.8
.mu.m, 2.9 .mu.m, 3.0 .mu.m, 3.1 .mu.m, 3.2 .mu.m, 3.3 .mu.m, 3.4
.mu.m, 3.5 .mu.m, 3.6 .mu.m 3.7 .mu.m, 3.8 .mu.m, 3.9 .mu.m, 4.0
.mu.m, 4.1 .mu.m, 4.2 .mu.m, 4.3 .mu.m, 4.4 .mu.m, 4.5 .mu.m, 4.6
.mu.m, 4.7 .mu.m, 4.8 .mu.m, 4.9 .mu.m, 5.0 .mu.m, 5.1 .mu.m, 5.2
.mu.m, 5.3 .mu.m, 5.4 .mu.m, 5.5 .mu.m, 5.6 .mu.m, 5.7 .mu.m, 5.8
.mu.m, 5.9 .mu.m, 6.0 .mu.m, 6.1 .mu.m, 6.2 .mu.m, 6.3 .mu.m, 6.4
.mu.m, 6.5 .mu.m, 6.6 .mu.m, 6.7 .mu.m, 6.8 .mu.m, 6.9 .mu.m, 7.0
.mu.m, 7.1 .mu.m, 7.2 .mu.m, 7.3 .mu.m, 7.4 .mu.m, 7.5 .mu.m, 7.6
.mu.m, 7.7 .mu.m, 7.8 .mu.m, 7.9 .mu.m, 8.0 .mu.m, 8.1 .mu.m, 8.2
.mu.m, 8.3 .mu.m, 8.4 .mu.m, 8.5 .mu.m, 8.6 .mu.m, 8.7 .mu.m, 8.8
.mu.m, 8.9 .mu.m, 9.0 .mu.m, 9.1 .mu.m, 9.2 .mu.m, 9.3 .mu.m, 9.4
.mu.m, 9.5 .mu.m, 9.6 .mu.m, 9.7 .mu.m, 9.8 .mu.m, 9.9 .mu.m, 10
.mu.m, 11 .mu.m, 12 .mu.m, 13 .mu.m, 14 .mu.m, 15 .mu.m, 16 .mu.m,
17 .mu.m, 18 .mu.m, 19 .mu.m, 20 .mu.m, 21 .mu.m, 22 .mu.m, 23
.mu.m, 24 .mu.m, 25 .mu.m, 26 .mu.m, 27 .mu.m, 28 .mu.m, 29 .mu.m,
More preferably, the bead comprises a diameter (or equivalent
measurement in a non-spheroidal particle) of between 1 .mu.m and 10
.mu.m.
[0261] In one particularly preferred embodiment, the beads are
AmpaSand (Trade mark: Genera Biosystems) beads produced by Genera
Biosystems. These beads are commercially available. However, the
present invention should not be considered in any way limited to
the use of these beads specifically.
[0262] The beads may be distinguished on the basis of the presence
or absence of one or more "optically detectable labels". Typically,
a particular bead may comprise 0, 1, 2, 3, 4, 5 optically
detectable labels. As used herein, the term "optically detectable
label" refers to any molecule, atom or ion which emits
fluorescence, phosphorescence and/or incandescence. Convenient
optically detectable labels include those which emit in the
ultraviolet (wavelength range of about 350 nm to about 3 nm),
visible (wavelength range of about 350 nm to about 800 nm, near
infrared (NIR) (wavelength range of about 800 nm to about 1500 nm)
and/or infrared (IR) (wavelength range of about 1500 nm to about 10
.mu.m) ranges. However, due to the ease of detection, in one
particularly preferred embodiment, the optically detectable label
is detectable in the visible wavelength range.
[0263] In further preferred embodiments of the subject invention,
the optically detectable label comprises one or more labels
selected from the list consisting of: a fluorophore, a
semiconductor particle, phosphor particle, a doped particle, or a
nanocrystal or quantum dot.
[0264] In certain particularly preferred embodiments of the present
invention, the optically detectable label is a fluorophore. As used
herein, the term "fluorophore" refers to any molecule which
exhibits the property of fluorescence. For the purposes herein, the
term "fluorescence" may be defined as the property of a molecule to
absorb light of a particular wavelength and re-emit light of a
longer wavelength. The wavelength change relates to an energy loss
that takes place in the process. The term "fluorophore" may
encompass a range of optically detectable labels such as chemical
fluorophores and dyes as well as quantum dots.
[0265] Particularly convenient optically detectable labels which
may be used in accordance with the present invention are embedded
fluorescent particles of semiconductors. These optically detectable
label particles may be so small that their properties and emission
become size dependent. Such small optically detectable label
particles are referred to in the art as semiconductor
nanoparticles, quantum dots, quantum wires, quantum rods or
nanocrystals or Q-particles. However, as used herein, the term
"Quantum Dot" or "QD" is to be understood to encompass all such
particles. Furthermore, optically detectable labels comprising QDs
may comprise approximately spherical or spheroidal particles, or
coated spherical or spheroidal particles. However, the term QD
should not be considered in any way to be limited to a spherical,
spheroidal, circular, cylindrical or any other morphology of a
"dot". For example, as used herein QDs may also comprise other
morphologies including, inter alia, rod-like, ellipsoidal, or
coated rod-like or ellipsoidal particles.
[0266] QDs consist of a nanometer-scale crystalline core of
semiconductor material; biologically active versions are typically
surrounded by a protective shell and external coat. For example,
QDs may comprise semiconductor crystallites which are about 2 nm to
about 30 nm in diameter and may contain approximately 50-500,000
atoms within the crystal, including luminescent crystals comprising
materials such as ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe, PbS, PbSe,
PbTe, HgS, HgSe, HgTe, Si, ZnO.
[0267] QDs fluoresce with a broad absorption spectrum and a narrow
emission spectrum. Unlike some other fluorophores, which have
distinct absorption spectra, QDs absorb light over a wide spectral
range, which allows quantum dots to be excited with a range of
light sources, such as lasers, arc lamps, or LEDs. Furthermore, a
collection of different QDs can be used in multiplex applications
using only a single excitation source. However, the emission
spectra for each dot is typically very narrow, in the order of
about 30 nm, the exact color depending on the particle's diameter
and composition. Furthermore, the narrow emission spectrum of QDs
permits spectral resolution of adjacent dots. In addition to the
benefits above, QDs are also relatively photostable, even during
intense excitation, and are brighter than fluorophores.
[0268] In light of the foregoing, it should also be understood that
the present invention encompasses the use of different sized
QDs.
[0269] Furthermore, the present invention contemplates QDs which
are treated with procedures such as thermal treatment, surface
modification, alloying, surface passivation or capping with surface
coatings to enable the QD to emit with high quantum yield and to
improve the photostability for long periods of time.
[0270] QDs are also commercially available from companies such as
Quantum Dot Corp. (QDC), which produces QDs such as the Qdot [Trade
Mark] 605 streptavidin conjugate, containing a cadmium-selenide
core that emits at 605 nm. Qdot conjugates that emit at 525, 565,
585, and 655 nm are also available. However, it should be
understood that the present invention is not limited in any way by
the particular composition of the QD (or any other optically
detectable label) and any QD (commercial or otherwise) may be
compatible with the present invention.
[0271] There are also many fluorescent dyes that are available in
the art which may be used as fluorophores in accordance with the
present invention. An important property of a fluorescent dye or
other fluorophore, which determines its potential for use is the
excitation wavelength of the fluorophore; it must match the
available wavelengths of the light source. However, many different
fluorescent dyes and other fluorophores will be familiar to those
of skill in the art, and the choice of fluorescent marker in no way
limits the subject invention. Particularly convenient fluorescent
dyes which may be used for the labelling of a substrate include
those discussed supra with regard to labelling of the PCR amplicon.
However, when choosing fluorescent labels, the emission spectra of
the fluorescent label used for the binding agent(s) should be
distinct from the emission spectrum of the label used for the
amplicon(s).
[0272] Two dyeing techniques are commonly used to fluorescently
label beads and microspheres--internal dyeing and external dyeing
(surface-labelling). The two techniques produce beads with unique
properties, each beneficial for different applications. Internal
dyeing produces extremely stable particles with typically narrow
fluorescence emissions. These beads often display a greater
resistance to photobleaching. As the fluorophore is inside the
beads, surface groups are available for use in conjugating ligands
(proteins, antibodies, nucleic acids, etc.) to the surface of the
bead. For this reason, internally labelled beads are typically used
in analyte-detection and immunoassay applications.
Surface-labelling involves conjugation of the fluorophore to the
bead surface. Because the fluorophores are on the surface of the
bead, they are able to interact with their environment just as the
fluorophores on a stained cell. The result is a bead standard that
exhibits the same excitation and emission properties as stained
cell samples, under a variety of different conditions, such as the
presence of contaminants or changes in pH. The "environmentally
responsive" nature of surface-labelled beads makes them ideally
suited for mimicking biological samples. Externally labelled beads
are frequently used as controls and standards in a number of
applications utilizing fluorescence detection. However, the present
invention contemplates the association of a bead with a fluorescent
label via any means.
[0273] The terms "phosphorescent beads", "phosphor beads" and
"phosphors" are used interchangeably herein. What constitutes a
phosphorescent optically detectable label would be readily
understood by one of skill in the art. However, by way of example,
which in no way limits the invention, suitable phosphors include
small particles of ZnS, ZnS:Cu, Eu oxide and other phosphors used
in display devices.
[0274] A optically detectable label comprising a "doped bead" may
include a particle which comprises occluded amounts of one or more
rare earth ions, such as Eu, Y, Yb, Sm and the like.
[0275] As used herein, the term "optically detectable label" should
be understood to also encompass multiple optically detectable
labels, mixtures of optically detectable labels, coated
nanocrystals, alloys and other complex mixtures that would be
evident to the skilled artisan. The use of all such optically
detectable labels is to be considered as being within the scope of
the methods and agents described herein.
[0276] Furthermore, the optically detectable label of the reactant
may comprise an optically detectable label incorporated into the
immobilized polynucleotide sequence which is bound or otherwise
associated with the bead, rather than being a label directly
associated with the bead per se.
[0277] The beads are generally labelled by the immobilized "tag" or
probe oligonucleotide. This tag carries an internal amine
(NH.sub.2) which is then modified by conjugation with a
succinimidyl ester of a dye. In the current set, the dye used is
BODIPY-TMR. By mixing labelled and unlabelled tags and then
conjugating this mix to the beads, one can produce classes of beads
with different levels of the fluorescent marker. The ratios
conveniently used are in a series of 1:5.sup.x; that is, the
different classes are produced by using the ratio of
unlabeled:labelled tags. This is generically exemplified below in
Table 4.
TABLE-US-00009 TABLE 4 Ratio of unlabelled to labelled tags Class
Rel amount Unlabeled Rel Amt Labeled All 0 All None All 0 1/5 5 1
1/25 25 1 1/125 125 1
[0278] The optically detectable label may be applied to a bead at a
range of concentrations or intensities, thereby providing another
basis on which particular beads may be "physiochemically
distinguishable". For example, if the maximum detectable intensity
of the signal of a particular optically detectable is deemed to be
100%, the label may be applied to a range of beads to give
intensities of 0%, 2%, 4%, 6%, 8%, 10%, 15%, 20%, 25%, 30%, 35%,
40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%.
[0279] In one embodiment, the beadset of reactants comprises beads
of 3.0 .mu.m, 3.5 .mu.m, 4.1 .mu.m, 5.0 .mu.m, 5.6 .mu.m and 6.8
.mu.m, wherein the 3.0 .mu.m, 3.5 .mu.m and 4.1 .mu.m diameter
beads are labelled at 0% and 100%, the 5.0 .mu.m diameter beads are
labelled at 0%, 100% and 20% and the 5.6 .mu.m and 6.8 .mu.m
diameter beads are labelled at 0%, 100%, 20% and 4%.
[0280] In another embodiment, the beadset of reactants comprises
beads of 3.0 .mu.m, 3.5 .mu.m, 3.77 .mu.m, 5.0 .mu.m, 5.6 .mu.m and
6.8 .mu.m. All bead sizes, (except for the 3.0 .mu.m which is
divided by zero level and high level of TMR), are divided according
to their respective zero level, medium level, and high level of
TMR.
[0281] In other embodiments, TMR levels are set such that during
bead to oligo conjugation, oligos with defined total oligo to
fluor-labelled ratios are used to determine discrete TMR groupings.
For example, zero levels of TMR have unlabelled oligos included in
conjugation; high levels of TMR have a 3:1 total oligo to
fluor-labelled ratio of oligos included in conjugation; and medium
levels of TMR have from a 150:1 to an 80:1 total oligo to
fluor-labelled ratio of oligos included in conjugation, depending
on bead size.
[0282] The immobilized polynucleotide component of the reactant,
e.g., cX.sub.n, cY and/or cZ may be bound to a bead using any
convenient means.
[0283] The immobilized polynucleotide may be encapsulated in beads
during their production or may be attached to their surface
post-production. The choice method used to associate the
polynucleotide with the bead will depend on the material used, as
would be readily ascertained by the skilled artisan. In addition,
further treatments, including silanization (coating of the
substrate with silanes), may be performed on the beads prior to
attachment of the polynucleotide in order to increase the binding
of said polynucleotide to the bead.
[0284] Generally, beads may be coated with any compound that will
covalently attach, or otherwise adsorb, to the surface of the bead,
and in addition the reactant should also have a chemical moiety for
the attachment of a polynucleotide, such as a thiol, amine or
carboxyl group. Non-limiting examples of compounds with these
characteristics include amino-terminated silanes such as
amino-propyltrimethoxysilane and amino-propyltriethoxysilane, as
well as thiol-terminated silanes such as
thio-propyltrimethoxysilane and thio-propyltriethoxysilane. In
addition to silanes, compounds such as poly-L-lysine that
non-covalently attach to the glass surface and electrostatically
adsorb the phosphate groups of the polynucleotide are also within
the scope of the present invention. Therefore, other compounds,
including other silanes suitable for the attachment of a
polynucleotide to a surface would be readily identified by the
skilled artisan, and the present invention is not limited by the
choice of compound.
[0285] The polynucleotide can be attached to the bead using any
convenient means; typically this is done by physical adsorption or
chemical linking. In addition, beads may be further coated with an
agent that promotes or increases the adsorption or binding of the
polynucleotide to the surface of the bead, such as amino-silanes.
However, other agents that perform this function will be readily
identified by persons of skill in the art. In some other
embodiments, the polynucleotide is covalently conjugated to the
bead by an oligo acrydite group reacting with a bead thiol
group.
[0286] In another embodiment, the nucleic acid molecule is bound to
the bead via the Universal Anchoring System (UAS) (Trade mark:
Genera Biosystems). Briefly, this system involves the use of a
"bridge" nucleic acid molecule to ligate a nucleic acid "tag"
sequence on the substrate with a target sequence. The "bridge"
sequence is partially complementary to the tag sequence and
partially complementary to the target sequence, such that the
bridge sequence may bind to both the tag and target sequences and
hold them in alignment such that the tag and target sequences may
be ligated using a ligase. The UAS is also commercially available.
However, the present invention should not be considered in any way
limited to this particular method of linking a nucleic acid
molecule to a substrate.
[0287] Determination of whether binding has occurred between an
amplicon and a reactant may be done using any methodology which
allows localization of a bound amplicon label to a particular
physiochemically distinguishable reactant. In a particularly
preferred embodiment, flow cytometry is used. [0288] Flow Cytometry
may be defined as a technology to measure properties of particles
or cells as they move, or flow, in liquid suspension. An analogy
may be made with a more familiar item of laboratory equipment, the
microscope, to further describe this technology. Most microscopes
have the following components:
A Light Source
[0289] The typical microscope uses a light bulb to illuminate the
object. In the flow cytometer, the light source is often a laser.
Lasers are used because they provide a very concentrated and
intense beam of monochromatic light. The monochromatic character of
the light is especially important in making fluorescence
measurements.
[0290] The Stage
[0291] In a microscope, the stage is movable to allow passage of
the object to the viewing field of an objective lens. In the flow
cytometer, the cells or particles exist in liquid suspension. The
liquid flows in response to air pressure, past an objective lens,
thus carrying the cells or particles through the viewing field.
[0292] The Lens
[0293] In both the microscope and the flow cytometer, the lens
collects light from the object.
[0294] The Filters
[0295] Some microscopes have filters to select those
characteristics of the light that are most important to the
observer. This is particularly true of fluorescence microscopes. In
fluorescence, dye molecules are excited by light of a
characteristic wavelength which then produce emitted light of a
longer wavelength. The filters remove the excitation light to allow
the emission light to be seen or measured.
[0296] The Detectors
[0297] In a microscope, the light detector is the observer. The
flow cytometer uses highly sensitive light detectors called
photomultiplier tubes (PMT's). The detectors must be able to
measure the brief flashes of emitted light from cells or particles
that are moving one at a time through the viewing field of the
objective lens at rates of up to several thousand per second.
[0298] Most flow cytometers can measure both Light Scatter and
Fluorescence.
[0299] In certain preferred embodiments, beads are detected and/or
sorted according to the methods of the present invention using flow
cytometry. The present invention, however, is in no way limited to
the particular flow cytometry method or apparatus hereinbefore
described. This example was provided only for illustrative
purposes, and the present invention is not to be limited to an
instrument or method according to the example provided.
[0300] Using flow cytometry, the size of a given bead may be
determined by the light scatter of the object.
[0301] Light scatter is the interaction of light and matter. All
materials, including beads, will scatter light. It is composed
largely of light that is reflected or refracted. The position from
which an object is viewed often determines what can be told about
it. In the flow cytometer, light scatter detectors are usually
located opposite the laser (relative to the cell or particle), and
to one side of the laser, in-line with the fluid-flow/laser beam
intersection. The measurements made by these detectors are called
forward light scatter and side light scatter, respectively.
[0302] Forward light scatter provides some information on the
relative size of individual cells or particles, whereas side light
scatter provides some information on the relative granularity of
individual beads. They are often used in combination to distinguish
the different major categories of white cells in unseparated
mammalian blood, but are useful in a wide variety of other assays
as well, such as the determination of the size of a
microparticle.
[0303] The present inventors have determined that flow cytometry is
able to distinguish between beads of about 3.0 .mu.m, about 3.5
.mu.m, about 4.1 .mu.m, about 5.0 .mu.m, about 5.6 .mu.m and about
6.8 .mu.m in diameter. The present inventors also have determined
that flow cytometry is able to distinguish between beads of about
3.0 .mu.m, about 3.5 .mu.m, about 3.77 .mu.m, about 5.0 .mu.m,
about 5.6 .mu.m and about 6.8 .mu.m in diameter. Still other bead
classes can be distinguished, such as between 5.0 and 5.6 and 5.6
and 6.8. Accordingly, the present inventors have identified that
flow cytometry can differentiate up to at least 6 different sizes
of beads.
[0304] In addition to size detection, flow cytometers typically
have one or more lasers and detectors for the detection of
fluorescence in a sample. Fluorescence is the property of a
molecule to absorb light of a particular wavelength and re-emit
light of a longer wavelength. The wavelength change relates to an
energy loss that takes place in the process. It is a characteristic
that makes fluorescence extremely useful: filters may be used to
exclude the excitation light from the light detector or the viewer.
Thus, the only light measured or seen originates from the
fluorophore. Interference from background or stray light striking
the detectors is extremely low.
[0305] There are many fluorescent dyes that are useful for flow
cytometry. They bind to a variety of cytochemical components, such
as nucleic acids; proteins; specific cell-membrane, nuclear, and
cytoplasmic receptors; intracellular ion molecules; and many more.
A key property of a fluorescent dye which determines it's potential
for use in a flow cytometric assay is the excitation wavelength,
i.e., it must match the available wavelengths of the light
source.
[0306] In other aspects, the present invention provides methods for
diagnosing an infection by a pathogenic analyte in a subject, said
method comprising: [0307] (i) obtaining a biological sample from
the subject which putatively comprises said pathogenic analyte;
[0308] (ii) isolating nucleic acid from said sample; [0309] (iii)
amplifying the nucleic acid from said sample using primers which
generate an amplicon which is distinct for said analyte or a
particular strain of said analyte; [0310] (iv) optionally
amplifying a control nucleic acid sequence from the subject; [0311]
(v) optionally effecting labelling of the amplicon(s) recited at
steps (iii) and/or (iv); [0312] (vi) hybridizing the labelled
amplicon(s) to a beadset of reactants wherein each member of the
beadset comprises a nucleic acid molecule having complementarity to
a nucleotide sequence of the analyte or a particular strain of the
analyte or a control nucleotide sequence, bound or otherwise
associated with a physiochemically distinguishable bead; and [0313]
(vii) determining to which of the reactants an amplicon has bound;
wherein the association of an amplicon with a particular reactant
is indicative of an infection by the analyte in the subject.
[0314] In other aspects, the hybridizing occurs in the presence of
at least one signal oligonucleotide sequence.
[0315] In other aspects, the hybridizing occurs in the presence of
at least one blocking oligonucleotide sequence.
[0316] As used herein the term "subject" refers to any organism may
be susceptible to infection by another analyte. As such, a
"subject" includes, but is not limited to animals, plants, fungi
and bacteria (which may be infected by bacteriophage). As used
herein the term "animal" preferably includes a mammal and more
preferably a primate including a lower primate and even more
preferably, a human. However, the term "animal" also specifically
includes livestock species such as cattle, horses, sheep, pigs,
goats and donkeys as well as laboratory animals. Examples of
laboratory test animals include mice, rats, rabbits, guinea pigs
and hamsters. Rabbits and rodent animals, such as rats and mice,
provide a convenient test system or animal model as do primates and
lower primates. Non-mammalian animals such as avian species,
zebrafish, amphibians (including cane toads) and Drosophila species
such as Drosophila melanogaster are also contemplated.
[0317] The "subject" may also be a non-animal such as a plant. The
term "plant" specifically includes plants of agricultural value
such as cereal plants (e.g., wheat, barley, oats, rye, triticale
and maize), rice, fruit trees (e.g., apples, bananas, mangoes and
oranges), sugarcane, horticultural crop plants (e.g., potatoes,
carrots and onions) and the like.
[0318] However, in certain preferred embodiments, the present
invention provides methods for diagnosing HPV infection in a human
subject, said method comprising: [0319] (i) obtaining a biological
sample from the human subject which putatively comprises HPV;
[0320] (ii) isolating nucleic acid from said sample; [0321] (iii)
amplifying the nucleic acid from said sample using primers which
generate an amplicon which is distinct for said analyte or a
particular strain of said analyte; [0322] (iv) optionally
amplifying a control nucleic acid sequence from the genomic DNA of
the human subject; [0323] (v) optionally effecting labelling of the
amplicon(s) recited at steps (iii) and/or (iv); [0324] (vi)
hybridizing the labelled amplicon(s) to a beadset of reactants
wherein each member of the beadset comprises a nucleic acid
molecule having complementarity to a nucleotide sequence of HPV or
a particular strain of HPV or a control nucleotide sequence, bound
or otherwise associated with a physiochemically distinguishable
substrate; and [0325] (vii) determining to which of the reactants
an amplicon has bound; wherein the association of an amplicon with
a particular reactant is indicative of HPV infection in the human
subject.
[0326] In other aspects, the hybridizing occurs in the presence of
at least one signal oligonucleotide sequence.
[0327] In other aspects, the hybridizing occurs in the presence of
at least one blocking oligonucleotide sequence.
[0328] In some aspects, the present invention also contemplates
methods for determining the risk of a human subject developing a
disease associated with one or more strains of HPV said method
comprising: [0329] (i) obtaining a biological sample from the human
subject which putatively comprises HPV; [0330] (ii) isolating
nucleic acid from said sample; [0331] (iii) amplifying the nucleic
acid from said sample using primers which generate an amplicon
which is distinct for said analyte or a particular strain of said
analyte; [0332] (iv) optionally amplifying a control nucleic acid
sequence from the genomic DNA of the human subject; [0333] (v)
optionally effecting labelling of the amplicon(s) recited at steps
(iii) and/or (iv); [0334] (vi) hybridizing the labelled amplicon(s)
to a beadset of reactants wherein each member of the beadset
comprises a nucleic acid molecule having complementarity to a
nucleotide sequence of HPV or a particular strain of HPV or a
control nucleotide sequence, bound or otherwise associated with a
physiochemically distinguishable substrate; and [0335] (vii)
determining to which of the reactant an amplicon has bound; wherein
the association of an amplicon with a particular reactant
comprising a polynucleotide which is complementary to a strain of
HPV associated with a particular disease, is indicative of an
increased risk said disease in the subject.
[0336] In other aspects, the hybridizing occurs in the presence of
at least one signal oligonucleotide sequence.
[0337] In other aspects, the hybridizing occurs in the presence of
at least one blocking oligonucleotide sequence.
[0338] When the labelling of the amplicons as outlined in part (v)
occurs, both the amplicons and the beads are labelled.
[0339] Exemplary diseases associated with one or more particular
strains of HPV include those presented in Table 3. Accordingly, in
some aspects, the present invention provides methods for diagnosing
an increased risk of a subject developing a particular disease by
specifically identifying which strain of HPV is infecting the
subject. In certain particularly preferred embodiments, the methods
are adapted to determining the risk of a human subject developing
cervical cancer.
[0340] The present invention further contemplates diagnostic kits
for use according to the methods described herein, including
diagnosing HPV infection in a human subject and/or assessing the
risk of a human subject developing an HPV-associated disease,
including cervical cancer. The kits comprise a beadset of reactants
which each comprise a polynucleotide which is complementary to a
nucleotide sequence of a particular strain of HPV, bound or
otherwise associated with a physiochemically distinguishable
substrate. Optionally, the kits may also comprise primers that bind
to conserved sequences among different strains of HPV, but generate
an amplicon which comprises distinct nucleotide sequences for each
strain of HPV wherein the amplicon generated is putatively
complementary to a polynucleotide bound to or otherwise associated
with one or more physiochemically distinguishable beads of the
kit.
[0341] In some embodiment, the beadsets of reactants comprise at
least group of beads, each comprising a diameter of any one of
about 3.0 .mu.m, about 3.5 .mu.m, about 4.1 .mu.m, about 5.0 .mu.m,
about 5.6 .mu.m and about 6.8 .mu.m. In a further preferred
embodiment, each size group of beads comprises one or more
sub-groups of microspheres each with a fluorescent label at a range
of different intensities. The fluorescent label is TMR and can be
applied at intensities of about 0%, about 4%, about 20% and about
100%.
[0342] In other embodiments, the beadsets of reactants comprises at
least group of beads, each comprising a diameter of any one of
about 3.0 .mu.m, about 3.5 .mu.m, about 3.77 .mu.m, about 5.0
.mu.m, about 5.6 .mu.m and about 6.8 .mu.m. TMR levels are set such
that during bead to oligo conjugation, oligos with defined total
oligo to fluor-labelled ratios are used to determine discrete TMR
groupings. For example, zero levels of TMR have unlabelled oligos
included in conjugation; high levels of TMR have a 3:1 total oligo
to fluor-labelled ratio of oligos included in conjugation; and
medium levels of TMR have from a 150:1 to an 80:1 total oligo to
fluor-labelled ratio of oligos included in conjugation, depending
on bead size.
[0343] In further embodiments, the kits comprises the primers GPS+
and GP6+ and optionally primers MLC1_F and MLC1_R.
[0344] In yet other embodiments, the kits comprise the primers
GP5d2+ and T7aGP6d+ and optionally primers mlc1.sub.--95f and T7
amlc1.sub.--275r.
[0345] In still other embodiments, the kits comprise the primers
GP5d3+ and T7aGP6d+* and optionally primers mlc1.sub.--95f and T7
amlc1.sub.--275r.
[0346] The present invention includes additional embodiments of
primer pairs wherein the individual forward (e.g., GPS+, GP5d2+,
etc.) and reverse primers (e.g., GP6+, T7aGP6d+) described herein
are combined with one another.
[0347] The kits may also be in the form of solid phase chips or
supports, commonly referred to as biochips. All or part of the
reagents used in the subject assay may be incorporated into a
biochip or miniaturized into a nanoassay. Although flow cytometry
is particularly useful in measuring outputs of the subject assay,
the biochips may be used to measure or automate other signals such
as those associated with whispering gallery mode assays.
[0348] Notwithstanding fluorescent intensities in a preferred
aspect of the multiplexing method, other forms of identification
are encompassed by the present invention. One such alternative
method includes whispering gallery mode (WGM) detection. In this
embodiment, a fluorescent marker is incorporated into beads of a
subset or incorporated or bonded to DNA on the surface of the
beads. This fluorescent marker can excite the WGMs with a laser or
unfocussed white light source or with filtered unfocussed white
light source.
[0349] WGMs allow only certain wavelengths of light to be emitted
from the particle. The result of this phenomenon is that the usual
broad emission (10-100 nm wide) bands from, for example, a
fluorophore become constrained and appear as a series of sharp
peaks corresponding effectively to standing mode patterns of light
within the particle. In accordance with the present invention, it
has been determined that the WGM profile is extremely sensitive to
changes at the surface of the microspheroidal particle and that the
WGM profile changes when the microspheroidal particle interacts
with analytes or molecules within its environment.
[0350] Accordingly, other aspects of the present invention
contemplate methods of detecting an analyte such as an amplicon
from an HPV strain comprising a strain-specific sequence, said
method comprising contacting at least one set of microspheroidal
particles with a sample putatively comprising said analyte, wherein
each particle within a set of microspheroidal particles comprises
an optically detectable label and an immobilized putative binding
partner of said analyte (e.g., a primer or probe capable of
binding, capturing or otherwise immobilizing an amplicon from an
HPV strain) wherein each particle set has a defined WGM profile,
wherein binding of said analyte to said immobilized binding partner
results in a change in said WGM profile of said at least one set of
microspheroidal particles which is indicative of the presence of
said analyte.
[0351] The methods of the present invention may be applied to
detect modulation in the WGM profile of a microspheroidal particle
wherein said modulation results from detection of binding or other
association of molecules in a sample to potential binding particles
immobilized to the surface of the microspheroidal particle.
Detection of binding reactions between an analyte and its binding
partner based on sensitive changes in WGM profiles enables the
identification and isolation of the analytes.
[0352] A feature of the present invention is that the
microspheroidal particles may be excited with a wide range of light
sources, facilitating measurement in many different WGM
profiles.
[0353] An "optically detectable label" may be any molecule, atom or
ion which emits fluorescence, phosphorescence and/or incandescence.
In some other preferred embodiments of the present invention, the
optically detectable label is a fluorophore, which may encompass a
range of optically detectable labels such as chemical fluorophores
and dyes as well as quantum dots.
[0354] In some embodiments, the present invention provides at least
one microspheroidal particle comprising a latex or silica particle
which is 1 .mu.m to 100 .mu.m in diameter, labelled with an
optically detectable label, such as a fluorophore or quantum dot,
the particle further comprising a putative binding partner of an
analyte to be detected. An example is a capture nucleic acid
molecule capable of binding to an HPV amplicon generated by the
amplification using two primers to a conserved region of the HPV
genome which flank a strain-specific region. The optically
detectable label is detectable at visible wavelengths and the
microspheroidal particle exhibits one or more WGM profiles. One or
more of the WGM profiles of the microspheroidal particle detectably
modulates when analytes interacts with the immobilized binding
partner on the particle. Any such change in WGM profile is
indicative of the presence of an analyte which has bound to its
binding partner.
[0355] Block oligos can be included in with the beads during
hybridization of single-stranded amplicon to beads. The block
oligos have deliberate points of difference from the corresponding
bead-probe binding regions of the single-stranded amplicons. There
can be a block oligo for each bead-probe in the mix. The block
oligos are intended to act as appropriately pitched filters. In the
context of a thermal denaturation followed by slow decrease in
temperature, most efficient hybridization events occur first.
Type-specific amplicons bind to the matching bead-probe according
to type early on. The block oligos can bind to and saturate the
bead-probes lower down the thermal profile. This can prevent
cross-type hybridization events (where between types there are more
points of difference at probe binding regions compared with the
block oligos) or other non-specific hybridisations such as other
amplicons, including primer-dimer products, from occurring. A block
oligo can be present for human control as well as the HPV types.
Examples of block oligos are described in Table 2 above. The level
of similarity between the block oligos and the complementary
sequence to the type-specific bead probe region (for which it is
designed to block) can be between 40% and 95%. Another example of
the level of similarity is between 75% and 85%.
[0356] Signal oligos can be used as alternatives to the use of
directly fluor labelled PCR primers for generating signal. Signal
oligos are fluor labelled probes that bind to amplicon products at
a site different from the bead-probe region to yield a
bead-probe/amplicon/signal oligo complex upon hybridization. The
advantages of their use would be: to preclude the requirement for
fluor-labelling (and excessively handling) PCR primer during
production, use of much less fluor-labelled oligo for equivalent
sensitivity (and cost benefits), reduction of fluor background such
that higher sensitivity can achieved without wash steps (handling
and risk benefits), increased sensitivity in the absence of block
oligos due to extra level of `nesting` in the hybridization
complex, and potential use of more of PCR product in the
`detection` steps. All of these benefits would facilitate a `single
tube` approach. Examples of signal oligos are described in Table 2
above.
[0357] Alternatively, a double stranded DNA-specific dye, such as
SYBR Green I dye may be used as a mode of attaching signal to
amplicon on bead alongside or instead of signal oligos.
[0358] The present invention is further described by the following
non-limiting examples.
Example 1
HPV Diagnosis--DNA Isolation and Amplification
[0359] An overview of the DNA extraction protocol used to isolate
DNA for the HPV diagnostic method is shown in FIG. 1.
[0360] As shown in FIG. 2, PCR was used to amplify the DNA sample.
The primers GP5d2+ and T7aGP6d+ were used to generate an amplicon
for any HPV strain which was present in the DNA sample. Primer
T7aGP6d+ comprised a fluorescent label, specifically A647 to allow
later visualization of the amplicon binding to the binding agents.
The viral amplicons generated comprised both a conserved region (Y)
which is conserved among all the strains of HPV examined and a
region which is variable (i.e., strain-specific) between HPV
strains, X.sub.n, wherein n represents a variable region associated
with each HPV strain. The immobilized binding partners on beads
specifically bind to the HPV strain-specific genome.
[0361] Also, an amplicon from the human subject genomic DNA was
also generated using the mlc1.sub.--95f and T7 amlc1.sub.--275r
primers to serve as a control. In this case, primer T7
amlc1.sub.--275ralso carried an A647 label.
Example 2
[0362] HPV Diagnosis--Multiplex Detection
[0363] The amplicons generated in Example 1 were hybridized to an
array of binding agents, each carrying a polynucleotide which is
complementary to the variable region of the putative viral amplicon
generated from each of HPV strains 6, 11, 16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 67 and 68 (X.sub.1 through X.sub.16). See
Table 2 for the nucleotide sequences of the capture nucleic acids
immobilized to the beads. Furthermore, the array can optionally
comprise a binding agent which comprises a polynucleotide which is
complementary to conserved region of the HPV viral amplicons (Y).
Finally, a binding agent comprising a polynucleotide which is
complementary to the sequence of the human control amplicon is
included. The capture nucleic acid may be DNA or RNA. If RNA is
used, a reverse transcriptase may be required to generate RNA from
the DNA amplicon.
[0364] Each of the binding agents in the array is comprises a
microsphere or bead with a distinct size and distinct intensity of
fluorescent (TMR) label. Beads comprising diameters of 3.0 .mu.m,
3.5 .mu.m, 3.77 .mu.m, 5.0 .mu.m, 5.6 .mu.m and 6.8 .mu.m may be
differentiated from each other using flow cytometry, as shown in
FIG. 4.
[0365] For each given size of microsphere, a fluorescent label
(TMR) was incorporated at relative intensities of 0%, approximately
150-80; 1 (medium), and approximately 3:1 (high). These label
intensities could be clearly distinguished using flow
cytometry.
Example 3
[0366] Comparison Of the Multiplex Detection Method with
Traditional HPV Diagnosis
[0367] Table 5, below, provides an overview comparing the multiplex
HPV detection method of the present invention with the current
histological method for HPV diagnosis.
TABLE-US-00010 TABLE 5 Comparison of HPV diagnostic methods HPV
Diagnostic Method Throughput Report Controls Present 1600 per all
13 "high risk" internal control, Invention day, per strains
individually positive control, instrument identified human gDNA
control Histological 350 per day "high risk" class no internal
control, based method generally identified "low risk" positive
control, "high risk" positive control
Example 4
Sensitivity Testing for Probe Methodology
[0368] Five microliters of each product was loaded alongside lanes
containing 5 microliters of HyperladderIV DNA ladder (FIG. 8).
Reactions were templated with 40000 copies of type-specific plasmid
(numbers in lanes indicate type) and subjected to 40 amplification
cycles using an annealing temperature of 44.degree. C. An `x` in
lanes indicates reactions not analysed due to evaporative loss
during PCR. A`-` in lanes indicates no template controls.
200 or 100 copies of type-specific plasmids along with 10 ng of
Jurkat human genomic DNA were used to template PCRs employing
GBHPVf3+ and GBHPVr1 multiplexed with MLC1.sub.--95f and
T7aMLC1.sub.--275r. Forty-eight amplification cycles were performed
using an annealing temperature of 44.degree. C. Analysis was
performed by flow cytometry following lambda exonuclease digestion
and hybridization to PapType probe beads. No template controls
yielded negative results across types. All types tested: 6, 11, 16,
18, 31, 45, 51, 52, 56, 58, 59, 66 and 68 yielded positive results
using 200 copies of type-specific plasmids. All above types except
types 51 and 59 yielded positive results using 100 copies of
type-specific plasmids, indicating a very sensitive and relatively
unbiased system.
[0369] When ranges are used herein for physical properties, such as
temperature or number of nucleotides in a sequence, all
combinations and subcombinations of ranges and specific embodiments
therein are intended to be included.
[0370] Those skilled in the art will appreciate that the invention
described herein is susceptible to variations and modifications
other than those specifically described. It is to be understood
that the invention includes all such variations and modifications.
The invention also includes all of the steps, features,
compositions and compounds referred to or indicated in this
specification, individually or collectively, and any and all
combinations of any to or more of said steps or features.
BIBLIOGRAPHY
[0371] Bonner and Laskey, Eur. J. Biochem. 46:83, 1974 [0372]
Chadwick et al., J. Virol. Methods 70:59-70, 1998 [0373] Chan and
Fox, Rev. Med. Microbiol. 10:185-196, 1999 [0374] Compton, Nature
350:91-92, 1991 [0375] Demidov and Broude (Eds.), "DNA
Amplification: Current Technologies and Applications", Horizon
Bioscience, 2004 [0376] Guatelli et al., Proc. Natl. Acad. Sci. USA
87:1874-1878, 1990 [0377] Hill, J. Clin. Ligand Assay 19:43-51,
1996 [0378] Kievits et al., J. Virol. Methods 35:273-286, 1991
[0379] Kuske et al., Appl. Environ. Microbiol. 64(7):2463-2472,
1998 [0380] Lizardi et al., Biotechnology 6:1197-1202, 1988 [0381]
Lyamichev et al., Nat. Biotechnol. 17:292-296, 1999 [0382] Marmur
and Doty, J. Mol. Biol. 5:109, 1962 [0383] Nelson and Krawetz,
Anal. Biochem. 207(1):97-201, 1992 [0384] Pawlotsky et al., J.
Virol. Methods 79:227-235, 1999 [0385] Ryan et al., Mol. Diagn.
4:135-144, 1999 [0386] Speel, Histochem. Cell Biol. 112:89-113,
1999 [0387] Todd et al., J. AIDS Hum. Retrovirol. 10:S35-S44, 1995
Sequence CWU 1
1
108124DNAArtificialSynthetic primer 1trtttgttac tgtkgtdgat acya
24225DNAArtificialSynthetic primer 2carytrtttg ttactgtkgt dgata
25323DNAArtificialSynthetic primer 3carytrtttg ttactgtkgt dga
23423DNAArtificialSynthetic primer 4aaycarytrt ttgttactgt kgt
23526DNAArtificialSynthetic primer 5tttgttactg tkgtdgatac yachcg
26629DNAArtificialSynthetic primer 6tttgttactg tkgtdgatac yachcgyag
29723DNAArtificialSynthetic primer 7gtkgtdgata cyachcgyag tac
23823DNAArtificialSynthetic primer 8gtdgatacya chcgyagtac haa
23935DNAArtificialSynthetic primer 9tgaaaaataa aytgyaaatc
atattcytcm mcatg 351026DNAArtificialSynthetic primer 10cayarytgaa
aaataaaytg yaaatc 261122DNAArtificialSynthetic primer 11trcayarytg
aaaaataaay tg 221219DNAArtificialSynthetic primer 12trcayarytg
aaaaataaa 191323DNAArtificialSynthetic primer 13tttgttactg
tggtagatac tac 231425DNAArtificialSynthetic primer 14gaaaaataaa
ctgtaaatca tattc 251523DNAArtificialSynthetic primer 15tttkttachg
tkgtdgatac yac 231625DNAArtificialSynthetic primer 16gaaahataaa
ytgyaadtca taytc 251723DNAArtificialSynthetic primer 17tttgttactg
tggtagatac tac 231825DNAArtificialSynthetic primer 18gaaaaataaa
ctgtaaatca tattc 251923DNAArtificialSynthetic primer 19tttkttachg
tkgtdgatac yac 232025DNAArtificialSynthetic primer 20gaaahataaa
ytgyaadtca taytc 252123DNAArtificialSynthetic primer 21tttkttachg
tkgtdgatac hac 232250DNAArtificialSynthetic primer 22aattctaata
cgactcacta taggggaaah ataaaytgya adtcataytc
502323DNAArtificialSynthetic primer 23tttkttachg tdgtdgayac hac
232450DNAArtificialSynthetic primer 24aattctaata cgactcacta
taggggaaah ataaaytgya rdtcawaytc 502523DNAArtificialSynthetic
primer 25tttkttachg tkgtdgatac hac 232650DNAArtificialSynthetic
primer 26aattctaata cgactcacta taggggaaah ataaaytgya adtcataytc
502723DNAArtificialSynthetic primer 27tttgttachg tdgtdgayac hac
232850DNAArtificialSynthetic primer 28aattctaata cgactcacta
taggggaaah ataaaytgya rdtcawaytc 502918DNAArtificialSynthetic
primer 29ggcacccaga caatacac 183045DNAArtificialSynthetic primer
30aattctaata cgactcacta tagggtaagt tgaagaggtg aagaa
453118DNAArtificialSynthetic primer 31ggcacccaga caatacac
183245DNAArtificialSynthetic primer 32aattctaata cgactcacta
tagggtaagt tgaagaggtg aagaa 453332DNAArtificialSynthetic primer
33caatcagctr tttgttactg tkgtdgatac ya 323430DNAArtificialSynthetic
primer 34acaatcaryt rtttgttact gtkgtdgata
303528DNAArtificialSynthetic primer 35acaatcaryt rtttgttact
gtkgtdga 283631DNAArtificialSynthetic primer 36ggaacaatca
rytrtttgtt actgtkgtdg a 313728DNAArtificialSynthetic primer
37ggaacaayca rytrtttgtt actgtkgt 283832DNAArtificialSynthetic
primer 38cagctttttg ttactgtkgt dgatacyach cg
323935DNAArtificialSynthetic primer 39cagctttttg ttactgtkgt
dgatacyach cgyag 354029DNAArtificialSynthetic primer 40attaccgtkg
tdgatacyac hcgyagtac 294128DNAArtificialSynthetic primer
41ctgttgtdga tacyachcgy agtachaa 284247DNAArtificialSynthetic
primer 42actcactata ggtgaaaaat aaaytgyaaa tcatattcyt cmmcatg
474344DNAArtificialSynthetic primer 43aatacgactc actataggca
yarytgaaaa ataaaytgya aatc 444443DNAArtificialSynthetic primer
44tctaatacga ctcactatag gtrcayaryt gaaaaataaa ytg
434543DNAArtificialSynthetic primer 45aattctaata cgactcacta
taggtrcaya rytgaaaaat aaa 434651DNAArtificialSynthetic probe
46aaagggagga cagctatgga catccgtaac tacatcttcc acatacacca a
514751DNAArtificialSynthetic probe 47aaagggagga cagctatgga
catctgtgtc taaatctgct acatacacta a 514851DNAArtificialSynthetic
probe 48aaagggagga cagctatgga cgtcattatg tgctgccata tctacttcag a
514951DNAArtificialSynthetic probe 49aaagggagga cagctatgga
cctcctgtac ctgggcaata tgatgctacc a 515051DNAArtificialSynthetic
probe 50aaagggagga cagctatgga ctgtttgtgc tgcaattgca aacagtgata c
515151DNAArtificialSynthetic probe 51aaagggagga cagctatgga
ctttatgcac acaagtaact agtgacagta c 515251DNAArtificialSynthetic
probe 52aaagggagga cagctatgga cgtctgtgtg ttctgctgtg tcttctagtg a
515351DNAArtificialSynthetic probe 53aaagggagga cagctatgga
ctctacctct atagagtctt ccataccttc t 515451DNAArtificialSynthetic
probe 54aaagggagga cagctatgga cacacaaaat cctgtgccaa gtacatatga c
515551DNAArtificialSynthetic probe 55aaagggagga cagctatgga
cagcactgcc actgctgcgg tttccccaac a 515651DNAArtificialSynthetic
probe 56aaagggagga cagctatgga ctgctgaggt taaaaaggaa agcacatata a
515751DNAArtificialSynthetic probe 57aaagggagga cagctatgga
cgtactgcta cagaacagtt aagtaaatat g 515846DNAArtificialSynthetic
probe 58aaagggagga cagctatgga cgcactgaag taactaagga aggtac
465951DNAArtificialSynthetic probe 59aaagggagga cagctatgga
ctctactact tcttctattc ctaatgtata c 516051DNAArtificialSynthetic
probe 60aaagggagga cagctatgga ctattaatgc agctaaaagc acattaacta a
516151DNAArtificialSynthetic probe 61aaagggagga cagctatgga
ctctactact actgaatcag ctgtaccaaa t 516248DNAArtificialSynthetic
probe 62aaagggagga cagctatgga ctccactact acagactcta ctgtacca
486351DNAArtificialSynthetic probe 63aaagggagga cagctatgga
ccaaacacag acacagagag acccacagac a 516430DNAArtificialSynthetic
oligonucleotide 64ttggtctatg tcgaagaagt agtaacggat
306530DNAArtificialSynthetic oligonucleotide 65ttagtctatg
ttgcagaatt agagacagat 306630DNAArtificialSynthetic oligonucleotide
66tctgatgtag aaatggctgc acaaaatgac 306730DNAArtificialSynthetic
oligonucleotide 67tggtaccatc aaattgcgca ggttcaggag
306830DNAArtificialSynthetic oligonucleotide 68gtatctctgt
tagcaatagc agctgaaaca 306930DNAArtificialSynthetic oligonucleotide
69gtactctcac ttgttacatg tgtccataaa 307030DNAArtificialSynthetic
oligonucleotide 70tcacttgaag agacagctga acagacagac
307130DNAArtificialSynthetic oligonucleotide 71agaagctatg
gtagactgta tagtggtaga 307230DNAArtificialSynthetic oligonucleotide
72gtcatttgta catggcagag gatattgtgt 307330DNAArtificialSynthetic
oligonucleotide 73tgttgcggaa agcgcaggag tgggagtgct
307430DNAArtificialSynthetic oligonucleotide 74ttataagtgc
tatccttatt aacgtcagca 307530DNAArtificialSynthetic oligonucleotide
75catatatact ttactgtact gtaccagtac 307624DNAArtificialSynthetic
oligonucleotide 76taccatcctt tgttacatca gtcc
247730DNAArtificialSynthetic oligonucleotide 77gtatagatta
gcaatagtag aagaagtaga 307830DNAArtificialSynthetic oligonucleotide
78ttagtaaatg tcctttttgc tgctttaata 307930DNAArtificialSynthetic
oligonucleotide 79atttgctaca ggtgattgag tagaagtaga
308027DNAArtificialSynthetic oligonucleotide 80tggtagagta
gtgtctgaag tagagga 278130DNAArtificialSynthetic oligonucleotide
81tgtctctggg tgtctctctg tctctgtttg 308223DNAArtificialSynthetic
oligonucleotide 82ttttttcatg kkgargarta tga
238321DNAArtificialSynthetic oligonucleotide 83ttttttcatg
kkgargarta t 218421DNAArtificialSynthetic oligonucleotide
84ttttttacag acacagacaa c 218522DNAArtificialSynthetic
oligonucleotide 85ttttttacag acacagacaa ca
228623DNAArtificialSynthetic oligonucleotide 86ttttttacag
acacagacaa cac 238712DNAArtificialSynthetic primer 87actcactata gg
128818DNAArtificialSynthetic primer 88aatacgactc actatagg
188921DNAArtificialSynthetic primer 89tctaatacga ctcactatag g
219024DNAArtificialSynthetic primer 90aattctaata cgactcacta tagg
249112DNAArtificialSynthetic primer 91actcactata gg
129218DNAArtificialSynthetic primer 92aatacgactc actatagg
189321DNAArtificialSynthetic primer 93tctaatacga ctcactatag g
219424DNAArtificialSynthetic primer 94aattctaata cgactcacta tagg
249525DNAArtificialSynthetic oligonucleotide 95aattctaata
cgactcacta taggg 259617DNAArtificialSynthetic primer 96gttttcccag
tcacgac 179717DNAArtificialSynthetic primer 97gtaaaacgac ggccagt
179817DNAArtificialSynthetic primer 98caggaaacag ctatgac
179922DNAArtificialSynthetic primer 99gccagggttt tcccagtcac ga
2210024DNAArtificialSynthetic primer 100gagcggataa caatttcaca cagg
2410118DNAArtificialSynthetic primer 101atttaggtga cactatag
1810224DNAArtificialSynthetic primer 102catacgattt aggtgacact atag
2410320DNAArtificialSynthetic primer 103taatacgact cactataggg
2010417DNAArtificialSynthetic primer 104attaaccctc actaaag
1710524DNAArtificialSynthetic primer 105gcgcgaaatt aaccctcact aaag
2410620DNAArtificialSynthetic primer 106tacacacagg tgtacacaga
2010720DNAArtificialSynthetic primer 107accaagtact ctacgtgttg
2010817DNAArtificialSynthetic primer 108ggcacccaga catacac 17
* * * * *